<SEC-DOCUMENT>0001047469-16-012558.txt : 20160426
<SEC-HEADER>0001047469-16-012558.hdr.sgml : 20160426
<ACCEPTANCE-DATETIME>20160426160411
ACCESSION NUMBER:		0001047469-16-012558
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20160615
FILED AS OF DATE:		20160426
DATE AS OF CHANGE:		20160426
EFFECTIVENESS DATE:		20160426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		161592039

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2228428zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg71401_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CATABASIS PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=246382,FOLIO='blank',FILE='DISK128:[16ZBB1.16ZBB71401]BA71401A.;5',USER='HYUNG',CD='26-APR-2016;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g890909.jpg" ALT="LOGO" WIDTH="676" HEIGHT="82">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dear Shareholders, </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
mission at Catabasis is to bring hope and life-changing therapies to patients and their families. To achieve this, we are developing a portfolio of product candidates in both rare
diseases and serious lipid disorders by leveraging our proprietary SMART linker drug discovery platform. Our SMART linker drug discovery platform enables us to engineer molecules that simultaneously
modulate multiple targets in a disease. Catabasis' accomplishments in 2015 have energized our team, and we have carried that momentum into 2016, during which we expect to make meaningful progress. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead clinical program is focused on the treatment of Duchenne muscular dystrophy (DMD) with CAT-1004, an investigational drug that we believe has the potential to be a
disease-modifying therapy for all patients affected by DMD, regardless of the underlying mutation. In 2016, we will continue our drive to bring a therapy to the boys who suffer from this devastating
degenerative disease with the
anticipated completion of our MoveDMD<SUP>SM</SUP> Phase&nbsp;2 clinical trial. CAT-1004 is an oral small molecule designed to inhibit NF-kB, a protein that is activated in DMD and drives
inflammation, fibrosis and muscle degeneration, and suppresses muscle regeneration. We are thankful for our relationships in the DMD community and intend to honor these relationships through our
continued commitment to this critical work. We also recognize that inhibiting NF-kB could be helpful to other patient populations beyond those affected by DMD, and we are evaluating additional
indications for CAT-1004. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also making substantial progress in our CAT-2054 program for severe lipid disorders. CAT-2054 inhibits SREBP, a master regulator of lipid metabolism, and we believe it has the
potential to significantly reduce LDL-C as well as have beneficial effects on liver health. We anticipate data from our Phase&nbsp;2 study of CAT-2054 in patients with hypercholesterolemia in 2016
and have already observed promising pre-clinical results for the CAT-2000 series in non-alcoholic steatohepatitis (NASH), including reduction in liver inflammation, fibrosis, and fat content. With
continued success, our strategic intention is to maximize the value of CAT-2054 through a partnership agreement with a company that is well suited to conduct the late-stage development with both
therapeutic area expertise and financial resources. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
we strive to fulfill our vision of being a premier rare disease company, our team continues to develop Catabasis' pre-clinical pipeline in rare diseases. This year, we are conducting
further pre-clinical studies with CAT-4001 in both amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia and plan to conduct IND-enabling activities. Importantly, our development of CAT-4001 for
the treatment of Friedreich's ataxia, a rare and debilitating neuromuscular disorder, is supported by grant funding from the Friedreich's Ataxia Research Alliance. Assuming success with these
activities, we intend to advance CAT-4001 into the clinic next year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015
was a foundational year for Catabasis. With the successful completion of our IPO, we have the resources to fuel progress in our clinical programs. We are extremely excited about our
prospects in 2016 and beyond, and we appreciate the continued support of our shareholders. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Sincerely,</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
<BR></FONT> <FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=95164,FOLIO='blank',FILE='DISK128:[16ZBB1.16ZBB71401]BC71401A.;9',USER='HYUNG',CD='26-APR-2016;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF&nbsp;2016 ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> To be held on June&nbsp;15, 2016  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are cordially invited to attend the 2016 Annual Meeting of Stockholders (the "Annual Meeting") of Catabasis Pharmaceuticals,&nbsp;Inc., which is scheduled
to be held on Wednesday, June&nbsp;15, 2016 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State Street, Boston, Massachusetts 02109. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Annual Meeting, the stockholders will consider and vote on the following matters: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Election
of two Class&nbsp;I Directors to our Board of Directors, to serve until the 2019 annual meeting of stockholders; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2016; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction
of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
can find more information, including the nominees for directors, in the attached Proxy Statement. The Board of Directors recommends that you vote in favor of each of proposals one
and two as outlined in the attached Proxy Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are pleased to take advantage of the Securities and Exchange Commission rules that allow us to furnish proxy materials to our stockholders on the internet. We believe these rules
allow us to provide you with the information that you need while lowering the costs of delivery and reducing the environmental impact of the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
invite all stockholders to attend the Annual Meeting in person. Stockholders of record at the close of business on April&nbsp;18, 2016, the record date for the Annual Meeting, are
entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. You may obtain directions to the location of the Annual Meeting by calling us at
617-349-1971. Whether or not you expect to attend the Annual Meeting in person, please vote your shares by proxy as promptly as possible to ensure your representation and the presence of a quorum at
the Annual Meeting. In addition to returning your proxy card by mail, you may vote your shares on the internet by visiting www.proxyvote.com or by telephone by calling 800-690-6903 and following the
recorded instructions. Your vote is important regardless of the number of shares you own. If you send in your proxy card or vote by telephone or the internet and then decide to attend the Annual
Meeting to vote your shares in person, you may still do so. Your proxy is revocable in accordance with the procedures set forth in the Proxy Statement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for
your shares to be voted. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>By order of the Board of Directors,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><BR>
<FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=2> Cambridge, Massachusetts<BR>
April&nbsp;26, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=768241,FOLIO='blank',FILE='DISK128:[16ZBB1.16ZBB71401]BE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<A NAME="bg71401_table_of_contents"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG71401A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg71401_catabasis_pharmaceuticals,_inc__cat02543"> </A>
<BR></FONT><FONT SIZE=2><B>  Catabasis Pharmaceuticals,&nbsp;Inc.<BR>  Proxy Statement<BR>  Table of Contents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG71401_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Proxy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proxy Statement</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Proxy"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da71401_important_information___da702379"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Important Information About the Annual Meeting and
Voting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da71401_important_information___da702379"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc71401_proposal_no._1_#151;election_of_class_i_directors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposal No.&nbsp;1&#151;Election of Class&nbsp;I
Directors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc71401_proposal_no._1_#151;election_of_class_i_directors"><FONT SIZE=2><BR>
6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de71401_corporate_governance"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Governance</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de71401_corporate_governance"><FONT SIZE=2><BR>
10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg71401_executive_officers"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Officers</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg71401_executive_officers"><FONT SIZE=2><BR>
19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg71401_executive_compensation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg71401_executive_compensation"><FONT SIZE=2><BR>
20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di71401_certain_relationships___di702230"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Person Transactions</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di71401_certain_relationships___di702230"><FONT SIZE=2><BR>
27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di71401_proposal_no._2_#151;ratificati__pro06343"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposal No.&nbsp;2&#151;Ratification of the Appointment of
Ernst&nbsp;&amp; Young&nbsp;LLP as Catabasis' Independent Registered Public Accounting Firm for the Fiscal Year Ending December&nbsp;31, 2016</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di71401_proposal_no._2_#151;ratificati__pro06343"><FONT SIZE=2><BR>
30</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71401_principal_stockholders"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71401_principal_stockholders"><FONT SIZE=2><BR>
32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71401_section_16(a)_benefici__dk702027"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Section&nbsp;16(a) Beneficial Ownership Reporting
Compliance</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71401_section_16(a)_benefici__dk702027"><FONT SIZE=2><BR>
35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71401_report_of_the_audit_committee"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of the Audit Committee</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71401_report_of_the_audit_committee"><FONT SIZE=2><BR>
36</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71401_householding"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Householding</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71401_householding"><FONT SIZE=2><BR>
37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71401_stockholder_proposals"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholder Proposals</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71401_stockholder_proposals"><FONT SIZE=2><BR>
37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71401_other_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71401_other_matters"><FONT SIZE=2><BR>
38</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=654948,FOLIO='blank',FILE='DISK128:[16ZBB1.16ZBB71401]BG71401A.;8',USER='HYUNG',CD='26-APR-2016;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da71401_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139<BR>
617-349-1971  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B><A NAME="Proxy"></A>PROXY STATEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>FOR THE 2016 ANNUAL MEETING OF STOCKHOLDERS<BR>
to be held on June&nbsp;15, 2016  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement and the proxy card contain information about the 2016 Annual Meeting of Stockholders of Catabasis Pharmaceuticals,&nbsp;Inc. (the "Annual
Meeting") to be held on Wednesday,
June&nbsp;15, 2016 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State Street, Boston, Massachusetts 02109. The Board of Directors of Catabasis
Pharmaceuticals,&nbsp;Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, unless expressly stated otherwise or the context otherwise
requires, the use of "Catabasis," "our," "we" or "us" refers to Catabasis Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance
with the recommendation of our Board of Directors with respect to each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at
the meeting by giving our corporate secretary written notice to that effect. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Report to Stockholders for the fiscal year ended December&nbsp;31, 2015 and this proxy statement and proxy card are first being made available to stockholders on or about
April&nbsp;26, 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Important Notice Regarding the Availability of Proxy Materials for<BR>
the Annual Meeting of Stockholders to be Held on June&nbsp;15, 2016:  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> This proxy statement and our 2015 Annual Report to Stockholders are<BR>
available for viewing, printing and downloading at www.proxyvote.com.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>A copy of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2015, as filed with the Securities and
Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder upon written request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building
1400E, Suite B14202, Cambridge, MA 02139. This proxy statement and our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2015 are also available on the SEC's website at
http://www.sec.gov and our website at www.catabasis.com.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=465612,FOLIO='1',FILE='DISK128:[16ZBB1.16ZBB71401]DA71401A.;5',USER='HYUNG',CD='26-APR-2016;11:05' -->
<A NAME="page_da71401_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da71401_important_information___da702379"> </A>
<A NAME="toc_da71401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purpose of the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Annual Meeting, our stockholders will consider and vote on the following matters: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Election
of two Class&nbsp;I directors to our Board of Directors, to serve until the 2019 annual meeting of stockholders;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending
December&nbsp;31, 2016; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Transaction
of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this proxy statement, we are not aware of any business to come before the meeting other than the first two items noted above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Recommendation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors unanimously recommends that you vote: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the election of the nominees to serve as Class&nbsp;I Directors on our Board of Directors for a three-year term; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year
ending December&nbsp;31, 2016. </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice of Internet Availability of Proxy Materials  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to rules adopted by the SEC, we have elected to provide access to our proxy materials via the internet. Accordingly, we are
sending a notice of internet availability of proxy materials to our stockholders. All stockholders will have the ability to access the proxy materials on the website referenced in the notice and to
request to receive a printed set of the proxy materials by mail. Instructions on how to access the proxy materials over the internet and how to request a printed copy may be found in the notice. In
addition, stockholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. We encourage stockholders to take advantage of the availability of
the proxy materials on the internet or through email to help reduce the environmental impact of our annual meetings. The proxy materials, including this proxy statement, a proxy card or voting
instruction card and our 2015 Annual Report on Form&nbsp;10-K, are also available for viewing, printing and downloading on the internet at www.proxyvote.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote at the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on the record date of April&nbsp;18, 2016 are entitled to receive notice of the
Annual Meeting and to vote the shares of our common stock that they held on that date. As of April&nbsp;18, 2016, there were 15,372,657 shares of common stock issued and outstanding. Each share of
common stock is entitled to one vote on each matter properly brought before the Annual Meeting. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Difference between a "stockholder of record" and a beneficial owner of shares held in "street
name"</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you have shares registered directly in your name with our transfer agent, American Stock Transfer&nbsp;&amp;
Trust
Company,&nbsp;LLC, then you are considered a "stockholder of record" of those shares. For these shares, your set of proxy materials has been made available to you directly by us. You may vote these
shares by proxy prior to the Annual Meeting by following the instructions contained on the proxy card. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=312031,FOLIO='2',FILE='DISK128:[16ZBB1.16ZBB71401]DA71401A.;5',USER='HYUNG',CD='26-APR-2016;11:05' -->
<A NAME="page_da71401_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you hold shares in a brokerage account or by a bank, trust or other nominee or
custodian, then you
are considered the beneficial owner of those shares, which are held in "street name." For these shares, your set of proxy materials has been made available to you by that organization. The
organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to instruct that organization as to
how to vote the shares held in your account by following the instructions contained on the voting instruction card provided to you by that organization. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How to Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you can vote your shares in one of two ways:
either by proxy or in person at the Annual Meeting. If you choose to vote by proxy, you may do so by telephone, via the internet or by mail. Each of these methods is explained below. </FONT> <FONT SIZE=2><B>If you hold your shares of Catabasis common
stock in multiple accounts, you should vote your shares as described in each set of proxy materials you
receive.</B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy
materials by mail and you live in the United States or Canada, you may vote by proxy by calling the toll free number found on the proxy card. You must have the control number that is on the proxy card
when voting. If you choose to vote by telephone, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may transmit your proxy voting
instructions&nbsp;via the internet by following the instructions provided on the notice of internet availability of proxy materials or the proxy card. You will need to have the control number that
is on the proxy card when voting. If you choose to vote via the internet, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy
materials by mail, you may vote by proxy by completing, signing and dating the proxy card and returning it in the envelope provided.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote in person
at the Annual Meeting. We will give you a ballot when you arrive. If you are the beneficial owner of shares held in "street name" and you wish to vote in person at the Annual Meeting, you must obtain
a legal proxy from the organization that holds your shares and present it with your ballot to the inspector of election at the Annual Meeting. Even if you plan to attend the Annual Meeting, we urge
you to vote your shares by proxy in advance of the Annual Meeting so that, if you should become unable to attend the Annual Meeting, your shares will be voted as directed by you. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Telephone
and internet voting for stockholders of record will be available up until 11:59&nbsp;p.m. Eastern Time on June&nbsp;14, 2016, and mailed proxy cards must be received by
June&nbsp;14, 2016 in order to be counted at the Annual Meeting. If the Annual Meeting is adjourned or postponed, these deadlines may be extended. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in street name (held for your account by a broker or
other
nominee): </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone or Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions
or a voting instruction form from your broker or other nominee if you are permitted to vote by telephone or internet.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions from your broker
or other nominee explaining how to vote your shares by mail.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you attend the Annual
Meeting, you may vote in person. To do so, you will need to show a picture identification as well as an account statement or a letter from the record holder indicating that you owned the shares as of
the record date, and obtain from the broker or other nominee who holds your shares a legal proxy or broker's proxy card and bring it with you to the meeting. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=146515,FOLIO='3',FILE='DISK128:[16ZBB1.16ZBB71401]DA71401A.;5',USER='HYUNG',CD='26-APR-2016;11:05' -->
<A NAME="page_da71401_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
voting deadlines and availability of telephone and internet voting for beneficial owners of shares held in "street name" will depend on the voting processes of the organization that
holds your shares. Therefore, we urge you to carefully review and follow the voting instruction card and any other materials that you receive from that organization. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quorum  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum of stockholders is necessary to hold a valid meeting. Our bylaws provide that a quorum will exist if stockholders holding a
majority of the shares of stock issued and outstanding and entitled to vote are present at the meeting in person or by proxy. Abstentions and broker non-votes count as present for establishing a
quorum but will not be counted as votes cast. Broker non-votes occur when your broker or other nominee submits a proxy for your shares (because
the broker or other nominee has received instructions from you on one or more proposals, but not all, or has not received instructions from you but is entitled to vote on a particular "discretionary"
matter) but does not indicate a vote for a particular proposal because the broker or other nominee either does not have the authority to vote on that proposal and has not received voting instructions
from you or has discretionary authority but chooses not to exercise it. If a quorum is not present, the meeting may be adjourned until a quorum is obtained. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ballot Measures Considered "Routine" and "Non-Routine"  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The election of directors (Proposal No.&nbsp;1) is a matter considered non-routine under applicable rules. A broker or other nominee
cannot vote without instructions on non-routine matters, and therefore there may be broker non-votes on Proposal No.&nbsp;1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for 2016 (Proposal No.&nbsp;2) is a matter considered
routine under applicable rules. A broker or other nominee may generally exercise discretionary authority and vote on routine matters. If they exercise this discretionary authority, no broker non-votes
are expected to exist in connection with Proposal No.&nbsp;2. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Votes Required to Elect Directors and Ratify Appointment of Ernst&nbsp;&amp; Young&nbsp;LLP  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be elected, a director must receive a plurality of the votes cast by stockholders entitled to vote at the meeting (Proposal
No.&nbsp;1). Shares represented by proxies that withhold authority to vote for a nominee for election as a director will not be counted as votes "for" a director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm requires the affirmative vote of the majority of the shares of
common stock present or represented by proxy and voted "for" or "against" such matter (Proposal No.&nbsp;2). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abstentions
and broker non-votes will not be counted as votes cast on any of the proposals. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Method of Counting Votes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote at the Annual Meeting on each matter to come before the Annual Meeting, including
the election of a director, for each share held by such stockholder as of the record date. Votes cast in person at the Annual Meeting or by proxy by mail, via the internet or by telephone will be
tabulated by the inspector of election appointed for the Annual Meeting, who will also determine whether a quorum is present. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=509289,FOLIO='4',FILE='DISK128:[16ZBB1.16ZBB71401]DA71401A.;5',USER='HYUNG',CD='26-APR-2016;11:05' -->
<A NAME="page_da71401_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revoking a Proxy; Changing Your Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may revoke your proxy before the vote is taken at the
meeting:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by submitting a new proxy with a later date before the applicable deadline either signed and returned by mail or transmitted using the
telephone or internet voting procedures described in the "How to Vote" section above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by voting in person at the meeting; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by filing a written revocation with our corporate secretary. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," you may submit new voting instructions by contacting your broker or other organization holding your account. You may also vote in person at the
Annual Meeting, which will have the effect of revoking any previously submitted voting instructions, if you obtain a legal proxy from the organization that holds your shares as described in the "How
to Vote" section above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
attendance at the Annual Meeting will not automatically revoke your proxy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Costs of Proxy Solicitation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will bear the costs of soliciting proxies. In addition to solicitations by mail, our directors, officers and regular employees,
without additional remuneration, may solicit proxies by telephone, facsimile, email, personal interviews and other means. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Results  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to announce preliminary voting results at the Annual Meeting and to publish final results in a Current Report on
Form&nbsp;8-K to be filed with the SEC within four business days following the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=333184,FOLIO='5',FILE='DISK128:[16ZBB1.16ZBB71401]DA71401A.;5',USER='HYUNG',CD='26-APR-2016;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc71401_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc71401_proposal_no._1_#151;election_of_class_i_directors"> </A>
<A NAME="toc_dc71401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1&#151;ELECTION OF CLASS I DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors is divided into three classes, with one class of our directors standing for election each year, for a three-year
term. Directors for each class are elected at the annual meeting of stockholders held in the year in which the term for their class expires and hold office until their resignation or removal or their
successors are duly elected and qualified. In accordance with our certificate of incorporation and bylaws, our directors may fill existing vacancies on the Board of Directors by appointment. The
members of the classes are divided as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;I directors are Jill C. Milne, Ron Laufer and Michael D. Kishbauch, and their term expires at the Annual Meeting; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;II directors are Nicholas Galakatos and Jean George, and their term will expire at the annual meeting of stockholders
to be held in 2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;III directors are Kenneth Bate, Michael Ross and Burt Adelman, and their term will expire at the annual meeting of
stockholders to be held in 2018. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation and bylaws provide that the authorized number of directors may be changed only by resolution of our Board of Directors. Our certificate of incorporation
and bylaws also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an
annual election of directors, and that any vacancy on our Board of Directors, including a vacancy resulting from an enlargement of our Board of Directors, may be filled only by vote of a majority of
our directors then in office. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors, on the recommendation of our nominating and corporate governance committee, has nominated Jill C. Milne and Michael D. Kishbauch for re-election as Class&nbsp;I
Directors at the Annual Meeting. The term of one of our directors, Ron Laufer, will expire at the Annual Meeting and he is not standing for reelection. Upon the expiration of Mr.&nbsp;Laufer's term,
the authorized size of our Board of Directors will be seven. Each Class&nbsp;I director that is elected at the Annual Meeting will be elected to serve for a three-year term that will expire at our
annual meeting of stockholders to be held in 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
no contrary indication is made, proxies in the accompanying form are to be voted for Dr.&nbsp;Milne and Mr.&nbsp;Kishbauch or, in the event that any of these candidates is not a
candidate or is unable to serve as a director at the time of election (which is not currently expected), for any substitute nominee who is designated by our Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have no formal policy regarding board diversity. Our priority in selection of board members is identification of members who will further the interests of our stockholders through
their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the
competitive landscape and adherence to high ethical standards. Certain individual skills and qualifications of our directors, which we believe contribute to the effectiveness of the Board of Directors
as a whole, are described in the paragraph below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=810045,FOLIO='6',FILE='DISK128:[16ZBB1.16ZBB71401]DC71401A.;9',USER='HYUNG',CD='26-APR-2016;13:24' -->
<A NAME="page_dc71401_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Regarding Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees
for director: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc71401_nominees_for_election_to_the_b__nom04880"> </A>
<A NAME="toc_dc71401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Nominees for Election to the Board of Directors<BR>  For a Three-Year Term Expiring at the<BR>  2019 Annual Meeting of Stockholders (Class&nbsp;I)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jill C. Milne, Ph.D.</I></B></FONT><FONT SIZE=2>, is a co-founder of our company and has served as a member of our Board of Directors and as our President and Chief
Executive Officer since June 2008. Prior to co-founding our company, Dr.&nbsp;Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when
it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr.&nbsp;Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of
the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of
biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr.&nbsp;Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley
College. We believe that Dr.&nbsp;Milne is qualified to serve on our Board of Directors because of her extensive leadership experience in the life sciences industry and her extensive knowledge of
our company based on her role as co-founder and Chief Executive Officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael D. Kishbauch</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since April 2016. He has served as a director of TetraLogic
Pharmaceuticals Corporation, a biopharmaceutical company, since November 2014. Mr.&nbsp;Kishbauch has also served as a director of Progenics Pharmaceuticals,&nbsp;Inc., a biopharmaceutical
company, since September 2013 and of Achillion Pharmaceuticals,&nbsp;Inc., or Achillion, a biotechnology company, since July 2004. Mr.&nbsp;Kishbauch previously served as President and Chief
Executive Officer of Achillion from July 2004 until his retirement in September 2013. Prior to that, he founded and served as President and Chief Executive Officer of OraPharma,&nbsp;Inc., a
commercial-stage pharmaceutical company focused on oral health care that was acquired by Johnson&nbsp;&amp; Johnson in 2003, from 1996 to 2004. Mr.&nbsp;Kishbauch also held senior management positions
with MedImmune,&nbsp;Inc., a biotechnology company, from 1992 to 1995. Mr.&nbsp;Kishbauch holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from
Wesleyan University. We believe that Mr.&nbsp;Kishbauch's extensive experience as an entrepreneur and manager and as a public company senior executive in the biopharmaceutical industry make him a
valuable contributor to our Board of Directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE ELECTION OF JILL C. MILNE AND MICHAEL D. KISHBAUCH.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc71401_members_of_the_board_of_direct__mem04554"> </A>
<A NAME="toc_dc71401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Members of the Board of Directors Continuing in Office<BR>  Term Expiring at the<BR>  2017 Annual Meeting of Stockholders (Class&nbsp;II)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="246pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=972591,FOLIO='7',FILE='DISK128:[16ZBB1.16ZBB71401]DC71401A.;9',USER='HYUNG',CD='26-APR-2016;13:24' -->
<A NAME="page_dc71401_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Nicholas Galakatos, Ph.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our Board of Directors and chair of the compensation committee since February 2012.
Dr.&nbsp;Galakatos is a co-founder of Clarus Ventures, a health care and life science venture capital firm, where he has served as Managing Director since its inception in 2005. Dr.&nbsp;Galakatos
has also served as a General Partner of MPM Asset Management&nbsp;II&nbsp;LLC since 2000 and as a General Partner of BioVentures III&nbsp;GP,&nbsp;LP since 2002. From 1997 to 2000,
Dr.&nbsp;Galakatos served as Vice President, New Business and a member of the Management Team at Millennium Pharmaceuticals. He was a founder of Millennium Predictive Medicine and TransForm
Pharmaceuticals, where he was also the Chairman and founding chief executive officer. Dr.&nbsp;Galakatos is a director of the public companies Portola Pharmaceuticals, NanoString Technologies and
Ophthotech Corporation, and formerly was the Lead Director of the public company Affymax and a director of the public companies Critical Therapeutics and AVEO Pharmaceuticals. Dr.&nbsp;Galakatos
received a B.A. in chemistry from Reed College and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, and performed postdoctoral studies in molecular biology at Harvard
Medical School. We believe that Dr.&nbsp;Galakatos is qualified to serve on our Board of Directors because of his extensive experience as a venture capital investor and a director of several public
companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jean George</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since October 2013. Since February 2002, she has been a Managing Director at
Advanced Technology Ventures, a venture capital fund, where she currently serves as the East Coast lead partner for healthcare investments. Since March 2012, Ms.&nbsp;George has served as Managing
Director at Lightstone Ventures, a venture capital firm. Ms.&nbsp;George currently serves as a member of the Board of Directors of the public companies Acceleron Pharma and Calithera Biosciences,
and previously served as a member of the Board of Directors of Portola Pharmaceuticals from 2005 to 2013 and of Zeltiq Aesthetics from 2005 to 2015. Ms.&nbsp;George also serves on the boards of the
private companies Hydra Biosciences and Thrasos Innovation. Ms.&nbsp;George holds a B.S. in Biology from the University of Maine and an M.B.A. from Simmons College Graduate School of Management.
Because of Ms.&nbsp;George's extensive investment and financial experience, we believe she is able to add valuable expertise in guiding the strategic direction of our Board of Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc71401_term_expiring_at_the_2018_annu__ter02405"> </A>
<A NAME="toc_dc71401_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Term Expiring at the 2018 Annual Meeting of Stockholders (Class&nbsp;III)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="246pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph. D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Kenneth Bate</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since January 2014, and as Co-Chairman since February 2016. From May 2009
until January 2012, Mr.&nbsp;Bate was the President and Chief Executive Officer of Archemix, a privately held biotechnology company. From January 2007 to April 2009, Mr.&nbsp;Bate was President
and Chief Executive Officer of NitroMed, a public pharmaceutical company. From March 2006 until January 2007, Mr.&nbsp;Bate was Chief Operating Officer and Chief Financial Officer of NitroMed. From
January 2005 to March 2006, Mr.&nbsp;Bate was employed at JSB-Partners, a banking and advisory services firm for biopharmaceutical and life sciences companies that he co-founded. From 2002 to
January 2005, Mr.&nbsp;Bate was head of commercial operations and Chief Financial Officer at Millennium Pharmaceuticals. Mr.&nbsp;Bate served as a member of the Board of Directors of Cubist
Pharmaceuticals,&nbsp;Inc., a public biopharmaceutical company, from June 2003 to January 2015 and was its non-executive Chair from March 2011 to January 2015. Mr.&nbsp;Bate served as a member of
the Board of Directors of BioMarin Pharmaceuticals Inc., a public biopharmaceutical company, from September 2010 to December 2015. Mr.&nbsp;Bate is a director of four other public biopharmaceutical
companies, AVEO Pharmaceuticals, Genocea Biosciences, Epizyme Pharmaceuticals, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=856447,FOLIO='8',FILE='DISK128:[16ZBB1.16ZBB71401]DC71401A.;9',USER='HYUNG',CD='26-APR-2016;13:24' -->
<A NAME="page_dc71401_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>and
Vanda Pharmaceuticals. During the last five years, Mr.&nbsp;Bate also served as a director of NitroMed and Coley Pharmaceutical Group. He holds a B.A. in Chemistry from Williams College and an
M.B.A. from The Wharton School of the University of Pennsylvania. We believe Mr.&nbsp;Bate's qualifications to serve on our Board of Directors include his operating, finance, commercial,
transactional and senior management experience in the industry, as well as his experience serving on the boards of directors of other public companies in the life sciences industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael Ross, Ph.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our Board of Directors since April 2010, and as Co-Chairman since February 2016. He
previously served as our Chairman from October 2010 until February 2016. Since 2002, Dr.&nbsp;Ross has served as a Managing Partner at SV Life Sciences Advisers,&nbsp;LLC, a venture capital firm
that he joined as a venture partner in 2001. Previously, Dr.&nbsp;Ross served as the Chief Executive Officer of CyThera, Carta Proteomics, MetaXen and Arris Pharmaceutical. Earlier in his career,
Dr.&nbsp;Ross was employed at Genentech, serving in several roles, including Vice President of Development and later Vice President of Medicinal and Biomolecular Chemistry. Dr.&nbsp;Ross currently
serves on the board of directors of Ophthotech Corporation, a biopharmaceutical company, and on the Board of Overseers of the Thayer School of Engineering at Dartmouth College. Dr.&nbsp;Ross
received an A.B. from Dartmouth College and a Ph.D. in chemistry from the California Institute of Technology and completed post doctorate training in molecular biology at Harvard University. We
believe that Dr.&nbsp;Ross is qualified to serve on our Board of Directors because of his extensive executive leadership experience and knowledge of the life sciences industry and his service on the
board of directors of other life sciences companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Burt Adelman, M.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our Board of Directors since April 2016. Dr.&nbsp;Adelman was Executive Vice President,
Research and Development and Chief Medical Officer of Dyax Corp., or Dyax, a biotechnology company, from February 2012 until its acquisition by Shire&nbsp;Plc in January 2016. Prior to joining Dyax,
he worked at Eleven Biotherapeutics,&nbsp;Inc., a biotechnology company, where he served as interim President of Research and Development from 2009 to 2010 and as Senior Advisor from February 2011
until December 2011. From 1991 to 2007, Dr.&nbsp;Adelman held positions of increasing responsibility at Biogen&nbsp;Inc. (formerly Biogen Idec&nbsp;Inc.), a global biotechnology company,
ultimately as Executive Vice President, Portfolio Strategy. Since 1998, Dr.&nbsp;Adelman has served as a lecturer in medicine at Harvard Medical School and as an Associate Physician at Brigham and
Women's Hospital. Dr.&nbsp;Adelman holds an M.D. from Cornell Medical College and a B.S. in biology from Trinity College. He completed residency training and a hematology fellowship at the Peter
Bent Brigham Hospital. We believe that Dr.&nbsp;Adelman's broad experience in drug development makes him a valuable contributor to our Board of Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=13,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=677979,FOLIO='9',FILE='DISK128:[16ZBB1.16ZBB71401]DC71401A.;9',USER='HYUNG',CD='26-APR-2016;13:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de71401_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de71401_corporate_governance"> </A>
<A NAME="toc_de71401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that good corporate governance is important to ensure that Catabasis is managed for the long-term benefit of our
stockholders. This section describes key corporate governance practices that we have adopted. We have adopted a code of business conduct and ethics, which applies to all of our officers, directors and
employees, and corporate governance guidelines and charters for our audit committee, our compensation committee, our nominating and governance committee and our science and technology committee. We
have posted copies of our code
of business conduct and ethics and corporate governance guidelines, as well as each of our committee charters, on the "Corporate Governance" page of the "Investors" section of our website,
www.catabasis.com, which you can access free of charge. Information contained on the website is not incorporated by reference in, or considered part of, this proxy statement. We will also provide
copies of these documents as well as our other corporate governance documents, free of charge, to any stockholder upon written request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square,
Building 1400E, Suite B14202, Cambridge, MA 02139, Attention: Investor Relations. We intend to disclose on our website any amendments to, or waivers from, our code of business conduct and ethics that
are required to be disclosed by law or NASDAQ listing standards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rule&nbsp;5605 of the NASDAQ Listing Rules requires a majority of a listed company's Board of Directors to be comprised of
independent directors within one year of listing. In addition, the NASDAQ Listing Rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and
nominating and corporate governance committees be independent, that audit committee members also satisfy independence criteria set forth in Rule&nbsp;10A-3 under the Exchange Act and that
compensation committee members also satisfy heightened independence requirements contained in the NASDAQ Listing Rules as well as Rule&nbsp;10C-1 under the Exchange Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
Rule&nbsp;5605(a)(2), a director will only qualify as an "independent director" if, in the opinion of our Board of Directors, that person does not have a relationship that would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to be considered independent for purposes of Rule&nbsp;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the
audit committee, the Board of Directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its
subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
determining the independence of the members of our compensation committee under the heightened independence requirements contained in the NASDAQ Listing Rules and Rule&nbsp;10C-1,
our Board of Directors is required to consider all factors specifically relevant to determining whether a director has a relationship with us that is material to that director's ability to be
independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of that director, including any
consulting, advisory or other compensatory fee paid by us to that director; and (2)&nbsp;whether that director is affiliated with our company, a subsidiary of our company or an affiliate of a
subsidiary of our company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has reviewed the composition of our Board of Directors and its committees and the independence of each director. Based upon information requested from and provided
by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that each of our directors, other than
Dr.&nbsp;Milne, is an "independent director" as defined under Rule&nbsp;5605(a)(2) of the NASDAQ Listing </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=504141,FOLIO='10',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<A NAME="page_de71401_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Rules.
Our Board of Directors also determined that Mr.&nbsp;Bate, Dr.&nbsp;Ross, Dr.&nbsp;Laufer and Mr.&nbsp;Kishbauch, who comprise our audit committee, and Mr.&nbsp;Bate and
Dr.&nbsp;Galakatos, who comprise our compensation committee, satisfy the independence standards for such committees established by the SEC and the NASDAQ Listing Rules, as applicable. In making such
determinations, our Board of Directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances our Board of Directors deemed
relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors is currently co-chaired by Mr.&nbsp;Bate and Dr.&nbsp;Ross, who both possess an in-depth knowledge of the
issues, opportunities and challenges we face. We believe they are the persons best positioned to ensure our Board of Directors' time and attention is focused on the most critical matters. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board's Role in Risk Oversight  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has responsibility for the oversight of the company's risk management processes and, either as a whole or
through its committees, regularly discusses with management our major risk exposures, the potential impact of these risks on our business and the steps we take to manage them. The risk oversight
process includes receiving regular reports from board committees and members of senior management to enable our board to understand the company's risk identification, risk management and risk
mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the audit committee reviews our policies with
respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and discussions with
management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of
our compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the
board, corporate disclosure practices, and potential conflicts of interest. The science and technology committee has responsibility for risk management in areas affecting our research and development.
While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board is regularly informed through committee reports about such risks. Matters
of significant strategic risk are considered by our board as a whole. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors met fourteen times during 2015, including telephonic meetings. During the year, each of our directors attended
75% or more of the total number of meetings of the Board of Directors and the committees on which he or she served. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have four standing committees: the audit committee, the compensation committee, the nominating and corporate governance committee
and the science and technology committee. Each of these committees has a written charter approved by our Board of Directors. A copy of each charter can be found on the "Corporate Governance" page of
the "Investors" section of our website at www.catabasis.com. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=15,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=202136,FOLIO='11',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<A NAME="page_de71401_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our audit committee are Dr.&nbsp;Ross, Mr.&nbsp;Bate, Dr.&nbsp;Laufer and Mr.&nbsp;Kishbauch. Mr.&nbsp;Bate is
the chair of the audit committee. Our Board of Directors has determined that each of Mr.&nbsp;Bate and Mr.&nbsp;Kishbauch qualifies as an audit committee financial expert within the meaning of SEC
regulations and the NASDAQ Listing Rules. In making this determination, our board has considered the formal education and nature and scope of each such director's previous experience, coupled with
past and present service on various audit committees. Our audit committee assists our Board of Directors in its oversight of our accounting and financial reporting process and the audits of our
financial statements. The audit committee met five times during 2015, including telephonic meetings. The audit committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the
work of our registered public accounting firm, including through the receipt and consideration of reports from such
firm; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and
related disclosures; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing our internal audit function, if any; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discussing our risk management policies; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing policies and procedures for the receipt, retention and treatment of accounting-related complaints and concerns;
</FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> meeting independently with our internal auditing staff, registered public accounting firm and management; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and
approving or ratifying any related person transactions; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the audit committee report required by SEC rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our audit committee meets the requirements for independence under current NASDAQ listing standards and SEC rules and regulations. Our Board of
Directors has determined that Mr.&nbsp;Bate, Dr.&nbsp;Ross, Dr.&nbsp;Laufer and Mr.&nbsp;Kishbauch are independent as independence is currently defined in applicable NASDAQ listing standards
and SEC rules and regulations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our compensation committee are Mr.&nbsp;Bate and Dr.&nbsp;Galakatos. Dr.&nbsp;Galakatos is the chair of the
compensation committee. Our compensation committee assists our Board of Directors in the discharge of its responsibilities relating to the compensation of our executive officers. The compensation
committee met four times during 2015. The compensation committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving, or making recommendations to our board with respect to, the compensation of our chief executive officer and
our other executive officers; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the evaluation of senior executives; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing and administering our cash and
equity incentive plans; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to our board with respect to director compensation; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>
 </FONT><FONT SIZE=2> reviewing and making recommendations to the Board of Directors relating to management succession planning; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the compensation committee report required
 by SEC rules, if applicable. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our compensation committee meets the requirements for independence under current NASDAQ listing standards and SEC rules and regulations. Our Board of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=16,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=464998,FOLIO='12',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<A NAME="page_de71401_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Directors
has determined that Mr.&nbsp;Bate and Dr.&nbsp;Galakatos are independent as independence is currently defined in applicable NASDAQ listing standards and SEC rules and regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee engaged Radford, an AON Hewitt company, as its compensation consultant during the fiscal year ended December&nbsp;31, 2015. Our compensation committee
considered the relationship that Radford has with us, the members of our Board of Directors and our executive officers. Based on the committee's evaluation, the compensation committee has determined
that Radford is serving as an independent and conflict-free advisor to the committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
assisted the committee in conducting a competitive compensation assessment for our executive officers and non-employee directors for the fiscal year ended December&nbsp;31,
2015. In evaluating the total compensation of our executive officers and non-employee directors, the compensation committee, with the assistance of Radford, established a peer group of 20 publicly
traded companies in the biopharmaceutical industry that was selected based on companies whose market capitalization, number of employees, maturity of product development pipeline and area of
therapeutic focus are similar to ours. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
peer group for our executive and director compensation benchmarking as approved by the compensation committee for 2015 was comprised of the following companies: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="32%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Aerie Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>ChemoCentryx,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Mirati Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Akebia Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Concert Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Reverance Therapeutics&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>aTyr Pharma&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Endocyte,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Stemline Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>BIND Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Epizyme,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Trevena,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Capricor Therapeutics,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Fate Therapeutics,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Verastem,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Cellular Biomedicine Group,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Genocea Biosciences&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Vital Therapies,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>GlycoMimetics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Xencor,&nbsp;Inc.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
then supplemented the peer group information with published survey data, which provided a broader market representation of companies and deeper position reporting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically,
our compensation committee has recommended that the independent members of the Board of Directors make most of the significant adjustments to annual compensation,
determined bonus and equity awards and established new performance objectives at one or more meetings held during the last quarter of the year. However, the compensation committee also considers
matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of our compensation strategy, potential
modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. The compensation committee has historically made recommendations to the
Board of Directors regarding compensation of employees at the level of vice president or above, making changes to pre-approved salary ranges, salary increases, equity awards, incentive payments and
pre-approved equity ranges for new hires and high performers and making material changes to benefits offered to our employees. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our nominating and corporate governance committee are Ms.&nbsp;George, Dr.&nbsp;Galakatos and Dr.&nbsp;Ross.
Dr.&nbsp;Ross is the chair of the nominating and corporate governance committee. The nominating and corporate governance committee met once during 2015. The nominating and corporate governance
committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identifying individuals qualified to become board members; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending to our board the persons to be nominated for election as
directors and to each committee of our Board of Directors; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=17,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=282352,FOLIO='13',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<A NAME="page_de71401_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and recommending corporate governance principles to the board; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing periodic evaluations of the board.
</FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our nominating and corporate governance committee meets the requirements for independence under current NASDAQ listing standards and SEC rules and
regulations. Our Board of Directors has determined that Ms.&nbsp;George, Dr.&nbsp;Galakatos and Dr.&nbsp;Ross are independent as independence is currently defined in applicable NASDAQ listing
standards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Science and Technology Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of the science and technology committee are Dr.&nbsp;Adelman and Dr.&nbsp;Ross. Dr.&nbsp;Adelman is the chair of the
science and technology committee. The science and technology committee was formed in April 2016 and therefore did not meet during 2015. The science and technology committee's responsibilities
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing, evaluating, and advising the board and management regarding the long-term strategic goals and objectives and the direction
of our research and development programs; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring and evaluating trends in research and development, and recommending to the Board of Directors and management emerging
technologies for building our technological strength; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending approaches to acquiring and maintaining technology positions; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT
SIZE=2> regularly reviewing our research and development pipeline; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assisting the Board of Directors with its oversight responsibility for enterprise risk management in areas
affecting our research and
development. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2015, the members of our compensation committee were Mr.&nbsp;Bate and Dr.&nbsp;Galakatos, each of whom is an independent
director. None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive
officers served as a director or member of our compensation committee during the fiscal year ended December&nbsp;31, 2015. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our
principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted on our website, www.catabasis.com, a
current copy of the code and all disclosures that are required by law or NASDAQ stock market listing standards concerning any amendments to, or waivers from, any provision of the code. Information
contained on the website is not incorporated by reference in, or considered part of, this proxy statement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nomination Process  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee is responsible for identifying individuals qualified to serve as directors,
consistent with criteria approved by our Board of Directors, and recommending the persons to be nominated for election as directors. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Qualifications  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In evaluating director nominees, the nominating and corporate governance committee will consider, among other things, the following
factors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reputation for integrity, honesty and adherence to high ethical standards; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=18,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=503343,FOLIO='14',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<A NAME="page_de71401_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> demonstrated business acumen, experience and ability to exercise sound judgments in matters that relate to the current and long-term
objectives of our company; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commitment to understand our company and its industry; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> interest and ability to understand the
sometimes conflicting interests of the various constituencies of our company, which include
stockholders, employees, customers, governmental units, creditors and the general public, and to act in the interests of all stockholders; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> diversity of expertise and experience in
substantive matters pertaining to our business relative to other board members. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee's goal is to assemble a Board of Directors that brings to the company a variety of perspectives and skills derived from high quality
business and professional experience. Moreover, the nominating and corporate governance committee believes that the background and qualifications of the Board of Directors, considered as a group,
should provide a significant mix of experience, knowledge and abilities that will allow the Board of Directors to fulfill its responsibilities. Nominees are not discriminated against on the basis of
race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee has not adopted a formal policy with respect to a fixed set of specific minimum qualifications for its candidates for membership on the
Board of Directors. The committee may consider such other facts, including, without limitation, diversity, as it may deem are in the best interests of our company and its stockholders. The committee
further believes it is appropriate for at least one member of our Board of Directors to meet the criteria for an "audit committee financial expert" as that phrase is defined under the regulations
promulgated by the SEC, and that a majority of the members of our Board of Directors be independent as required under
the NASDAQ qualification standards. The committee believes it is appropriate for our chief executive officer to serve as a member of our Board of Directors. Our directors' performance and
qualification criteria are reviewed periodically by the nominating and corporate governance committee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Identification and Evaluation of Nominees for Directors  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nominating and corporate governance committee identifies nominees for director by first evaluating the current members of our Board
of Directors willing to continue in service. Current members with qualifications and skills that are consistent with the nominating and corporate governance committee's criteria for Board of Director
service and who are willing to continue in service are considered for re-nomination, balancing the value of continuity of service by existing members of our Board of Directors with that of obtaining a
new perspective or expertise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any member of our Board of Directors does not wish to continue in service or if our Board of Directors decides not to re-nominate a member for re-election, the nominating and
corporate governance committee identifies a new nominee that meets the criteria above. The committee generally inquires of our Board of Directors and members of management for their recommendations.
The committee may also review the composition and qualification of the Boards of Directors of our competitors, and may seek input from industry experts or analysts. The nominating and corporate
governance committee reviews the qualifications, experience and background of suggested candidates. Final candidates, if other than our current directors, would be interviewed by the members of the
nominating and corporate governance committee and by certain of our other independent directors and executive management. In making its determinations, the nominating and corporate governance
committee evaluates each individual in the context of our Board of Directors as a whole, with the objective of assembling a group that can best contribute to the success of our company and represent
stockholder interests through the exercise of sound judgment. After review and deliberation of all feedback and data, the nominating and corporate governance committee makes its recommendation to our
Board of Directors. The nominating and corporate governance committee utilized a third-party search firm to identify Board of Director candidates, including Dr.&nbsp;Adelman and
Mr.&nbsp;Kishbauch, both </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=19,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=535706,FOLIO='15',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<A NAME="page_de71401_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
whom joined our Board of Directors in April 2016. The nominating and corporate governance committee may in the future continue to use a third party search firm in those situations where particular
qualifications are required or where existing contacts are not sufficient to identify an appropriate candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not received director candidate recommendations from our stockholders and do not have a formal policy regarding consideration of such recommendations. However, any
recommendations received from stockholders will be evaluated in the same manner that potential nominees suggested by board members, management or other parties are evaluated. We do not intend to treat
stockholder recommendations in any manner different from other recommendations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our bylaws, stockholders wishing to suggest a candidate for director should write to our corporate secretary. In order to give the nominating and corporate governance committee
sufficient time to evaluate a recommended candidate and/or include the candidate in our proxy statement for the 2017 annual meeting, the recommendation should be received by our corporate secretary at
our principal executive offices in accordance with our procedures detailed in the section below entitled "Stockholder Proposals." Such submissions must state the nominee's name, together with
appropriate biographical information and background materials, and information with respect to the stockholder or group of stockholders making the recommendation, including the number of shares of
common stock owned by such stockholder or group of stockholders, as well as other information required by our bylaws. We may require any proposed nominee to furnish such other information as we may
reasonably require to determine the eligibility of such proposed nominee to serve as an independent director or that could be material to a reasonable stockholder's understanding of the independence,
or lack thereof, of such proposed nominee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Attendance at Annual Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our corporate governance guidelines, members of our Board of Directors are responsible for attending our Annual Meeting, and we
encourage all of our directors to attend. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Communications with Our Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders seeking to communicate with our Board of Directors should submit their written comments to Catabasis
Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139, Attention: Corporate Secretary. The corporate secretary will forward such communications to each
member of our Board of Directors; provided that, if, in the opinion of our corporate secretary, it would be inappropriate to send a particular stockholder communication to a specific director, such
communication will only be sent to the remaining directors (subject to the remaining directors concurring with such opinion). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2015, we did not provide any cash compensation to Dr.&nbsp;Milne, our Chief Executive Officer, for her service as a director.
Dr.&nbsp;Milne's compensation as an executive officer is set forth below under "Executive Compensation&#151;2015 Summary Compensation Table." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, our Board of Directors adopted an amended director compensation program, which became effective as of January&nbsp;1, 2016. Under this director compensation program,
we pay our non-employee directors a cash retainer for service on the Board of Directors and for service on each committee on which the director is a member. The Co-Chairmen of the Board of Directors
and the Chairmen of each committee receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the
amount of such payment is prorated for any portion of such quarter that the director is not serving on our Board of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=20,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=566315,FOLIO='16',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<A NAME="page_de71401_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Directors.
The fees paid to non-employee directors for service on the Board of Directors and for service on each committee of the Board of Directors on which the director is a member are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Member<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Chairman<BR>
Incremental<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Corporate Governance Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Science and Technology Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event co-chairmen are appointed, the retainer for Chairman of the Board will be divided equally between the co-chairmen.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending our board of director and committee meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, under our director compensation program, each new non-employee director elected to our Board of Directors receives an option to purchase 13,000 shares of our common stock.
Each of these options will vest in equal annual installments over a three-year period measured from the date of grant, subject to the director's continued service as a director. Further, on the date
of the first board meeting held after each annual meeting of stockholders, each non-employee director that has served on our Board of Directors for at least six months will receive an option to
purchase 6,500 shares of our common stock. Each of these options will vest in full after a one-year period measured from the date of grant, subject to the director's continued service as a director.
The exercise price of all options granted to directors will equal the fair market value of our common stock on the date of grant. Options granted to non-employee directors become exercisable in full
upon a change in control of Catabasis. Prior to the 2016 amendment, the initial award to directors was for 11,094 shares and the annual award was for 4,437. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
policy is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our
directors' interests with those of our stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to our initial public offering, or IPO, in June 2015, we did not have a formal non-employee director compensation policy. However, we provided compensation for board service to
Mr.&nbsp;Bate in the form of an annual cash retainer and a stock option grant. Other than Mr.&nbsp;Bate, none of our non-employee directors received any compensation prior to our IPO, other than
reimbursement for reasonable travel and out-of-pocket expenses incurred in connection with attending Board of Directors and committee meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with our director compensation program that was in effect at the time, we granted options to purchase 11,094 shares of our common stock to each of Dr.&nbsp;Ross,
Dr.&nbsp;Galakatos, Ms.&nbsp;George, Mr.&nbsp;Laufer and Mr.&nbsp;Bate in June 2015 in connection with our IPO. We did not grant any other equity-based awards to our non-employee directors
during 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=21,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=785302,FOLIO='17',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<A NAME="page_de71401_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information regarding compensation earned by our non-employee directors during 2015. Dr.&nbsp;Adelman and Mr.&nbsp;Kishbauch joined our Board of
Directors in 2016 and received no compensation from us in 2015. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned or<BR>
Paid In Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>131,347</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,990</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110,837</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ron Laufer, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,067</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>112,914</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>137,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts included in the "Option awards" column reflect the aggregate grant date fair value of awards granted during 2015 calculated in accordance with
Financial Accounting Standards Board, or FASB, Accounting Standard Codification, or ASC, Topic&nbsp;718. Assumptions used in the calculation of these amounts are included in Note&nbsp;2 to the
consolidated financial statements included in our Annual Report on Form&nbsp;10-K previously filed with the SEC. As of December&nbsp;31, 2015:</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Ross held a stock option to purchase 11,094 shares of common stock, none of which were vested as of December&nbsp;31,
2015; the shares are scheduled to vest in equal annual installments over a three-year period with the first annual vesting date to occur on June&nbsp;30, 2016; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Galakatos held a stock option to purchase 11,094 shares of common stock, none of which were vested as of
December&nbsp;31, 2015; the shares are scheduled to vest in equal annual installments over a three-year period with the first annual vesting date to occur on June&nbsp;30, 2016; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Ms.&nbsp;George held a stock option to purchase 11,094 shares of common stock, none of which were vested as of December&nbsp;31,
2015; the shares are scheduled to vest in equal annual installments over a three-year period with the first annual vesting date to occur on June&nbsp;30, 2016; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Laufer held a stock option to purchase 11,094 shares of common stock, none of which were vested as of December&nbsp;31,
2015; the shares are scheduled to vest in equal annual installments over a three-year period with the first annual vesting date to occur on June&nbsp;30, 2016; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Bate held a stock option to purchase 20,977 shares of common stock, 4,941 shares of which were vested as of
December&nbsp;31, 2015; 4,942 shares are scheduled to vest in equal monthly installments through and including January&nbsp;1, 2018, and 11,094 of the shares are scheduled to vest in equal annual
installments over a three-year period with the first annual vesting date to occur on June&nbsp;30, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$14,423 paid to Mr.&nbsp;Bate pursuant to a retainer agreement for service on our Board of Directors prior to our IPO. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=22,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=750246,FOLIO='18',FILE='DISK128:[16ZBB1.16ZBB71401]DE71401A.;9',USER='HYUNG',CD='26-APR-2016;11:16' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg71401_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg71401_executive_officers"> </A>
<A NAME="toc_dg71401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding our executive officers as of April&nbsp;15, 2016: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph. D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer, Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne Donovan, M.D., Ph. D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rick Modi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Business Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deirdre A. Cunnane</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President, General Counsel</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
biography of Dr.&nbsp;Milne can be found under "Proposal No.&nbsp;1: Election of Class&nbsp;I Directors." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Joanne M. Donovan, M.D., Ph.D.</I></B></FONT><FONT SIZE=2>, has served as our Chief Medical Officer since July 2011. Since 1989, she has worked as a staff physician
at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr.&nbsp;Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate
clinical professor of medicine. From 1998 to July 2011, Dr.&nbsp;Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme
Corporation, a biotechnology company, which she joined through its acquisition of GelTex. Dr.&nbsp;Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute
of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in
gastroenterology at the Brigham and Women's Hospital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Rick Modi</I></B></FONT><FONT SIZE=2> has served as our Chief Business Officer since January 2015. Prior to joining Catabasis, Mr.&nbsp;Modi worked from July 2013
to January 2015 as the Senior Vice President of Global Marketing at InterMune,&nbsp;Inc., which was acquired by Hoffman-La Roche AG in 2014. From February 2008 to July 2013, Mr.&nbsp;Modi worked
at MedImmune,&nbsp;LLC, a wholly-owned biologics research and development subsidiary of AstraZenca&nbsp;plc, in positions of increasing responsibility, ultimately as the Vice President of
Corporate Strategy and Portfolio Management. From January 2002 to February 2008, Mr.&nbsp;Modi worked at Janssen Biotech,&nbsp;Inc. (formerly Centocor Biotech,&nbsp;Inc.), a wholly-owned
biotechnology subsidiary of Johnson&nbsp;&amp; Johnson, serving in several positions, including the Associate Director of Global Market Development. Mr.&nbsp;Modi holds an M.B.A. from The Wharton
School of the University of Pennsylvania and a B.S. in pharmacy from the University of Iowa. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Deirdre A. Cunnane</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President and General Counsel since November 2015. Prior to joining Catabasis,
Ms.&nbsp;Cunnane served as General Counsel at Advanced Technology Ventures, or ATV, from January 2006 to October 2015, and at Lightstone Ventures, or Lightstone, from its founding in January 2012
until October 2015. Prior to ATV and Lightstone, Ms.&nbsp;Cunnane was an investment officer at BancBoston Ventures and Deputy General Counsel at BancBoston Capital. Ms.&nbsp;Cunnane started her
law career with, and later became a Partner in, Goodwin Procter,&nbsp;LLP's corporate department. Ms.&nbsp;Cunnane holds a J.D. from Boston College Law School and a B.S. in Finance from the Boston
College School of Management. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=493803,FOLIO='19',FILE='DISK128:[16ZBB1.16ZBB71401]DG71401A.;7',USER='HYUNG',CD='26-APR-2016;11:18' -->
<A NAME="page_dg71401_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg71401_executive_compensation"> </A>
<A NAME="toc_dg71401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers, or
NEOs. Our NEOs for 2015 are Jill C. Milne, Joanne M. Donovan, Rick Modi and Michael Jirousek. This section also provides qualitative information regarding the manner and context in which compensation
is awarded to and earned by our executive officers and is intended to place in perspective the data presented in the tables and narrative that follow. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2015 Summary Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation earned in 2015 and 2014 by our NEOs. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:102pt;"><FONT SIZE=1><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,102pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>420,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,575,611</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,442</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,155,454</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>375,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>302,265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>798,555</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rick Modi(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
327,564</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
128,373</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
808,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
76,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,341,307</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Business Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
360,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
130,979</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,442</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
592,781</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Medical Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>333,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85,099</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>455,133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Jirousek, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
254,305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
36,929</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
61,294</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
348,261</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
700,789</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Former Chief Scientific Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>329,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>161,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>589,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Bonus" column represent discretionary annual cash bonuses awarded to our NEOs.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of share-based compensation awarded during the year computed
in accordance with the provisions of FASB ASC, Topic 718. See Note&nbsp;2 to the consolidated financial statements included in our Annual Report on Form&nbsp;10-K previously filed with the SEC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "All Other Compensation" column reflect, for each NEO, the cost to us of life insurance premiums paid for the NEO, and, in the
case of Mr.&nbsp;Modi, $75,642 in accrued relocation expenses paid in 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Modi
joined Catabasis in January 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$347,243 in severance benefits payable between October 2015 and September 2016 pursuant to the Transition Agreement (as defined below); see
"Employment Agreements, Severance and Change in Control Arrangements&#151;Transition and Separation Agreement."  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative to Summary Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and
granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our
expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company.
We do not target a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=24,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=621598,FOLIO='20',FILE='DISK128:[16ZBB1.16ZBB71401]DG71401A.;7',USER='HYUNG',CD='26-APR-2016;11:18' -->
<A NAME="page_dg71401_1_21"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation committee recommends to our Board of Directors our executives' compensation. Our compensation committee typically reviews and discusses management's proposed
compensation with the chief executive officer for all executives other than the chief executive officer. The compensation committee, without the applicable members of management present, discusses
management's recommendations and ultimately approves the recommendation of compensation of our executive officers. During 2015, our compensation committee engaged Radford, as its independent
compensation consultant, to review our executive compensation peer group and program design and assess our executives' compensation relative to comparable companies. See "Corporate
Governance&#151;Committees of the Board of Directors&#151;Compensation Committee" for more information about Radford. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salary.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In 2015, we paid annual base salaries to Dr.&nbsp;Milne, Mr.&nbsp;Modi, Dr.&nbsp;Donovan and Dr.&nbsp;Jirousek in the
amounts of
$420,000, $327,564, $360,360 and $254,305, respectively. We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our NEOs.
None of our NEOs is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual bonus.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The compensation committee of our Board of Directors may, in its discretion, award bonuses to our NEOs from time to time.
We typically
establish annual bonus targets based around a set of specified corporate goals for our NEOs, along with individual goals, and conduct an annual performance review to determine the attainment of such
goals. Our management may propose bonus awards to the compensation committee of the Board of Directors or the Board of Directors primarily based on such review process. Our compensation committee
makes a recommendation to the Board of Directors regarding eligibility requirements for and the amount of such bonus awards. With respect to 2015, we awarded and paid bonuses of $158,400 to
Dr.&nbsp;Milne, $128,373 to Mr.&nbsp;Modi and $100,000 to Dr.&nbsp;Donovan, in each case as determined by our Board of Directors upon the recommendation of the compensation committee. With
respect to Dr.&nbsp;Milne, the amount of her bonus was based on her bonus target and the achievement of 90% of our company goals, and, with respect to Mr.&nbsp;Modi and Dr.&nbsp;Donovan, the
amounts of their respective bonuses was based on their respective bonus targets and the achievement of both individual and company goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity incentives.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive
officers, or any
formal equity ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to
align the interests of our executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes
our executive officers to remain in our employment during the vesting period. Accordingly, we typically grant stock option awards at the start of employment to each executive officer and our other
employees and our compensation committee and Board of Directors periodically review the equity incentive compensation of our NEOs and other employees and from time to time may grant equity incentive
awards to them in the form of stock options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
grants in connection with initial employment, vesting begins on the initial date of employment. Time vested stock option grants to our executives and other employees typically vest
25% on the first anniversary of grant or, if earlier, the initial employment date and 2.0833% per month thereafter, through the fourth anniversary of the vesting commencement date, and have a term of
10&nbsp;years from the grant date. In March 2015, our compensation committee granted options to purchase 9,338, 5,058, 4,669 and 8,171 shares of our common stock to Dr.&nbsp;Milne,
Mr.&nbsp;Modi, Dr.&nbsp;Donovan and Dr.&nbsp;Jirousek, respectively, as part of a review of their overall compensation. In addition, following the closing of our initial public offering, or IPO,
in July 2015, Dr.&nbsp;Milne received an option to purchase 160,000 shares of our common stock. In 2014, our board of directors granted options to purchase 58,365, 31,128 and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=25,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=549061,FOLIO='21',FILE='DISK128:[16ZBB1.16ZBB71401]DG71401A.;7',USER='HYUNG',CD='26-APR-2016;11:18' -->
<A NAME="page_dg71401_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>25,291
shares of our common stock to Dr.&nbsp;Milne, Dr.&nbsp;Donovan and Dr.&nbsp;Jirousek, respectively, as part of a review of their overall compensation. The exercise price of all options is
equal to the fair market value of our common stock on the date of grant. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at 2015 Fiscal Year End Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding outstanding stock options held by our NEOs as of December&nbsp;31, 2015. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,276</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/28/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,858</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,966</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,399</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,338</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>160,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rick Modi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
119,066</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9.51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2/11/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
27,237</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/6/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,531</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,926</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,430</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,172</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,669</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Jirousek, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
84,276</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2/28/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,858</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,916</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,212</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,171</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through July&nbsp;9, 2016.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through January&nbsp;17, 2017.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through December&nbsp;31, 2017.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards vested on March&nbsp;25, 2106. The remaining unvested awards are scheduled to vest in equal monthly installments through
March&nbsp;25, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards are scheduled to vest on July&nbsp;7, 2106. The remaining unvested awards are scheduled to vest in equal monthly installments
through July&nbsp;7, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards vested on January&nbsp;25, 2016. The remaining unvested awards are scheduled to vest in equal monthly installments through
January&nbsp;25, 2019.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=26,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=876406,FOLIO='22',FILE='DISK128:[16ZBB1.16ZBB71401]DG71401A.;7',USER='HYUNG',CD='26-APR-2016;11:18' -->
<A NAME="page_dg71401_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements, Severance and Change in Control Arrangements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Employment Agreements</B></FONT><FONT SIZE=2> with Current NEOs </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into an employment agreement with Dr.&nbsp;Milne, dated as of April&nbsp;7, 2010. The employment agreement confirms Dr.&nbsp;Milne's title, compensation
arrangements, and eligibility for benefits made available to employees generally. The employment agreement with Dr.&nbsp;Milne provides that she is eligible to receive an annual cash bonus, as
determined by the board of directors in its sole discretion, with a target of 40% of her annual base salary earned in such particular calendar year, which percentage shall be subject to adjustment
from time to time by the Board of Directors in its sole discretion. The Board of Directors determines the amount of the bonus, if any, based on its assessment of Dr.&nbsp;Milne's performance and
that of Catabasis against appropriate goals established annually by the Board of Directors after consultation with Dr.&nbsp;Milne. The Board of Directors has approved for 2016 a target cash bonus
(expressed as a percentage of base salary) of up to 40% for Dr.&nbsp;Milne. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors has approved for 2016 a target cash bonus (expressed as a percentage of base salary) of up to 45% for Mr.&nbsp;Modi and up to 35% for Dr.&nbsp;Donovan, as
determined in the sole discretion of the Board of Directors based on its assessment of their respective performance and that of Catabasis against established annual goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of Drs. Milne and Donovan and Mr.&nbsp;Modi is an employee at will and is entitled to certain benefits upon termination pursuant to our Severance Benefits Plan, or the Severance
Plan, which was adopted by the Board of Directors in April 2016, as further described below. In connection with the adoption of the Severance Plan, each of Drs. Milne and Donovan and Mr.&nbsp;Modi
has acknowledged that their entitlement to severance benefits is governed by the terms of the Severance Plan and that the terms of their employment agreement or offer letter, as applicable, have been
superseded in their entirety by the terms of the Severance Plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Severance Plan provides eligible full time executives holding the title of vice president or above ("Covered Employees") certain
severance benefits upon a termination without cause (as defined in the Severance Plan) or a resignation for good reason (as defined in the Severance Plan), including in each case within one year
following a change in control (as defined in the Severance Plan) (each, a "Covered Termination"). Pursuant to the Severance Plan, each Covered Employee who is subject to a Covered Termination is
entitled to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuation of such Covered Employee's monthly base salary (as defined in the Severance Plan) for a period ranging from six months to
18&nbsp;months (the "Severance Period") following such termination depending on the title/role of the Covered Employee and the type of Covered Termination; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payment by Catabasis of a portion of the cost of COBRA continuation of benefits coverage for the Covered Employee and his or her
applicable dependents for no longer than the Covered Employee's applicable Severance Period or until the Covered Employee commences new employment and is eligible for new plan coverage, if sooner,
subject to certain conditions set forth in the Severance Plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any unpaid annual bonus in respect to any completed bonus period which has ended prior to the date of the Covered Employee's Covered
Termination and which the Board of Directors deems granted to the Covered Employee in its discretion pursuant to Catabasis's contingent compensation program; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of the chief executive officer of Catabasis, a bonus amount equal to one-half of the average annual bonus paid to the
chief executive officer over the three calendar years preceding </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=27,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=531407,FOLIO='23',FILE='DISK128:[16ZBB1.16ZBB71401]DG71401A.;7',USER='HYUNG',CD='26-APR-2016;11:18' -->
<A NAME="page_dg71401_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>the
calendar year in which the Covered Termination occurs, which bonus shall be prorated to reflect the number of days served in the calendar year in which such Covered Termination occurs; and </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of a change in control termination, full vesting of any unvested equity awards. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receipt
of any severance benefits under the Severance Plan requires that the Covered Employee: (a)&nbsp;comply with the provisions of any applicable noncompetition, nonsolicitation,
and other obligations to us; and (b)&nbsp;execute and deliver a suitable waiver and release under which the Covered Employee releases and discharges us and our affiliates from and on account of any
and all claims that relate to or arise out of the employment relationship between us and the Covered Employee, which release will become binding within 60&nbsp;days following the Covered Employee's
termination of employment. If a Covered Employee dies following a Covered Termination but before such Covered Employee has received all of the severance benefits to which such Covered Employee is
entitled under the Severance Plan, the remaining payments will be made to the Covered Employee's designated beneficiary or estate. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides that the following employees will not be eligible for severance benefits, except to the extent specifically determined otherwise by the Severance Plan's
administrator:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is terminated for cause (as defined in the Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who retires, terminates employment as a result of an inability to performs his or her duties due to physical or mental
disability or dies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who voluntarily terminates his or her employment, except in the case of a Covered Termination for good reason (as defined
in the Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is employed for a specific period of time in accordance with the terms of a written employment agreement; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who promptly becomes employed by another member of the controlled group of entities of which Catabasis (or its successor
in the change in control (as defined in the Severance Plan)) is a member as defined in Sections&nbsp;414(b) and (c)&nbsp;of the Internal Revenue Code of 1986, as amended. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides for recoupment of severance benefits under specified circumstances if the Covered Employee fails to comply with the terms of the Severance Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan supersedes (i)&nbsp;existing severance plans and separation policies applying to Covered Employees with respect to any termination that would constitute a Covered
Termination and (ii)&nbsp;the provisions of any agreements between any Covered Employee and us that provide for severance benefits. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=28,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=176329,FOLIO='24',FILE='DISK128:[16ZBB1.16ZBB71401]DG71401A.;7',USER='HYUNG',CD='26-APR-2016;11:18' -->
<A NAME="page_dg71401_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the schedule of severance payments our NEOs would receive, assuming a qualifying termination occurred on December&nbsp;31, 2015 and assuming the
Severance Plan had been in effect on such date. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cash<BR>
Severance<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>COBRA<BR>
Continuation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Accelerated<BR>
Vesting of Equity<BR>
Awards<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Jill C. Milne, Ph.D.</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>440,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,376</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>526,254</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change of control</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>660,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,376</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38,816</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>104,201</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>863,394</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Rick Modi</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination without cause</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>375,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination upon a change of control</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>375,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Joanne M. Donovan, M.D., Ph.D.</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>270,270</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>296,148</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change of control</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>270,270</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,552</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>378,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
amount represents 12&nbsp;months base salary, each at the rate in effect immediately prior to the executive's termination of employment and, in the
case of Dr.&nbsp;Milne for a change in control termination, 18&nbsp;months base salary.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
amount represents 50% of the average bonus received by Dr.&nbsp;Milne for the three most recently completed years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
amount represents paid health coverage for 12&nbsp;months and, in the case of Dr.&nbsp;Milne for a change in control termination, 18&nbsp;months
paid health coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
values of accelerated vesting of equity awards included in the table above are based on the intrinsic values of such unvested awards on
December&nbsp;31, 2015 (i.e.&nbsp;the difference between the closing price of our company's common stock on the NASDAQ Global Market on that date and the exercise price multiplied by the number of
shares for which vesting would have been accelerated).  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also entered into employee confidentiality, non-competition and proprietary information agreements with each of our NEOs. Under the employee confidentiality, non-competition and
proprietary information agreements, each NEO has agreed (1)&nbsp;not to compete with us during his or her employment and for a period of 18&nbsp;months after the termination of his or her
employment, (2)&nbsp;not to solicit our employees during his employment and for a period of 18&nbsp;months after the termination of his or her employment, (3)&nbsp;to protect our confidential
and proprietary information and (4)&nbsp;to assign to us related intellectual property developed during the course of his or her employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transition and Separation Agreement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2015, we entered into a transition and separation agreement, or the Transition Agreement, with Dr.&nbsp;Jirousek. The terms of
the Transition Agreement superseded the terms of Dr.&nbsp;Jirousek's then-existing employment agreement with Catabasis. Pursuant to the terms of the Transition Agreement, Dr.&nbsp;Jirousek
terminated his employment as of September&nbsp;30, 2015, and was appointed as a member of our Scientific Advisory Board for a term ending on September&nbsp;30, 2016. Pursuant to the terms of the
Transition Agreement, Dr.&nbsp;Jirousek received severance benefits equal to monthly salary continuation at his annual base rate of $340,000 and reimbursement for medical and dental benefits for
12&nbsp;months. Dr.&nbsp;Jirousek was also paid a one-time bonus amount equal to one half of the average annual bonuses paid to him in the three calendar years preceding the calendar year of his
termination. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=29,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=94501,FOLIO='25',FILE='DISK128:[16ZBB1.16ZBB71401]DG71401A.;7',USER='HYUNG',CD='26-APR-2016;11:18' -->
<A NAME="page_dg71401_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) retirement plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section&nbsp;401(k) of
the Internal Revenue Code. In general, all of our employees are eligible to participate, beginning on the first day of the month following commencement of their employment. The 401(k) plan includes a
salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $18,000 in 2015, and have the amount of
the reduction contributed to the 401(k) plan. Participants over the age of 50 are entitled to an additional catch-up contribution up to the statutorily prescribed limit, equal to $6,000 in 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=30,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=666733,FOLIO='26',FILE='DISK128:[16ZBB1.16ZBB71401]DG71401A.;7',USER='HYUNG',CD='26-APR-2016;11:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di71401_1_27"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di71401_certain_relationships___di702230"> </A>
<A NAME="toc_di71401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of transactions since January&nbsp;1, 2015 to which we have been a party, and in which any of our
directors, executive officers or beneficial owners of more than 5% of our voting securities, or affiliates or immediate family members of any of our directors, executive officers or beneficial owners
of more than 5% of our voting securities, had or will have a direct or indirect material interest. We believe the terms obtained or consideration that we paid or received, as applicable, in connection
with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unrelated third parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance and Change in Control Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "Executive Compensation&#151;Employment Agreements, Severance and Change in Control Arrangements" above for a discussion of
these arrangements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification of Officers and Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware
law. In addition, we have entered into indemnification agreements with each of our directors and executive officers that may be broader in scope than the specific indemnification provisions contained
in the Delaware General Corporation Law. These indemnification agreements require us, among other things, to indemnify each such director and executive officer for some expenses, including attorneys'
fees, judgments, fines and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. In addition, we
maintain standard policies of insurance under which coverage is provided to our directors and officers against losses arising from claims made by reason of breach of duty or other wrongful act, and to
us with respect to payments which may be made by us to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;B Preferred Stock Financing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2015, we issued and sold an aggregate of 13,062,965 additional shares of our series&nbsp;B preferred stock at a price per
share of $0.9503, for an aggregate purchase price of $12.4&nbsp;million. The following table sets forth the number of shares of our series&nbsp;B preferred stock purchased by our directors,
executive officers and 5% stockholders and their affiliates and the aggregate purchase price paid for such shares. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of Series&nbsp;B<BR>
Preferred Stock<BR>
Purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Purchase Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SV Life Sciences Fund V,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,859,593</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,767,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SV Life Sciences Fund V Strategic Partners,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,299</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,346</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarus Lifesciences II,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,828,998</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,738,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MedImmune Ventures,&nbsp;Inc.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,084,882</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,030,963</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced Technology Ventures VIII,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>753,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>716,046</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lightstone Ventures,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>442,646</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>420,647</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lightstone Ventures (A),&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,312</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57,315</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>105,229</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>George Milne</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>333,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>316,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rick Modi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,614</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,261</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Jirousek</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,261</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,570,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,244,133</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=31,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1006216,FOLIO='27',FILE='DISK128:[16ZBB1.16ZBB71401]DI71401A.;4',USER='HYUNG',CD='26-APR-2016;11:05' -->
<A NAME="page_di71401_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the series&nbsp;B financing, we entered into an amended and restated investor rights agreement, dated as of March&nbsp;17, 2015, with certain stockholders, who
purchased our preferred stock, including some of our directors and 5% stockholders and their affiliates and entities affiliated with our officers and directors. The amended and restated investor
rights agreement provides these holders the right to demand that we file&nbsp;a registration statement or request that their shares be covered by a registration statement that we are otherwise
filing. In addition, the holders of warrants to purchase shares of our preferred stock have rights under those warrants to become party to the amended and restated investor rights agreement following
exercise of the warrants, following which they will have, with respect to the shares acquired on exercise of the warrants, the same rights to require us to register the shares as the other investor
parties to the amended and restated investor rights agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purchases in Initial Public Offering  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial owners of more than 5% of our voting securities and their affiliates purchased an aggregate of 1,250,000 shares of our
common stock in our IPO in June 2015 at the price to the public of $12.00 per share. The following table sets forth the number of shares of our common stock purchased and the aggregate cash purchase
price paid by each of these entities in our IPO. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:93pt;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,93pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Common<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with SV Life Sciences</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>391,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,693,080</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarus Lifesciences II,&nbsp;L.P.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>376,695</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,520,340</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MedImmune Ventures,&nbsp;Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>223,439</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,681,268</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced Technology Ventures VIII,&nbsp;L.P.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>155,188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,862,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Lightstone Ventures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>103,588</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,243,056</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies and Procedures for Related Person Transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has adopted a written related person transaction policy to set forth policies and procedures for the review and
approval or ratification of related person transactions. This policy covers any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which
we were or are to be a participant, the amount involved exceeds $120,000, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of
goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
related person transaction policy contains exceptions for any transaction or interest that is not considered a related person transaction under SEC rules as in effect from time to
time. In addition, the policy provides that an interest arising solely from a related person's position as an executive officer of
another entity that is a participant in a transaction with us will not be subject to the policy if each of the following conditions is met:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person and his or her immediate family members are not involved in the negotiation of the terms of the transaction with us
and do not receive any special benefits as a result of the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount involved in the transaction equals less than the greater of $200,000 or 5% of the annual gross revenue of the company
receiving payment under the transaction. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=32,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=396758,FOLIO='28',FILE='DISK128:[16ZBB1.16ZBB71401]DI71401A.;4',USER='HYUNG',CD='26-APR-2016;11:05' -->
<A NAME="page_di71401_1_29"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that any related person transaction proposed to be entered into by us must be reported to our general counsel or chief financial officer and will be reviewed and
approved by our audit committee in accordance with the terms of the policy, prior to effectiveness or consummation of the transaction whenever practicable. The policy provides that if our general
counsel or chief financial officer determines that advance approval of a related person transaction is not practicable under the circumstances, our audit committee will review and, in its discretion,
may ratify the related person transaction at the next meeting of the audit committee. The policy also provides that alternatively, our general counsel or chief financial officer may present a related
person transaction arising in the time period between meetings of the audit committee to the chair of and audit committee, who will review and may approve the related person transaction, subject to
ratification by the audit committee at the next meeting of the audit committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the policy provides that any related person transaction previously approved by the audit committee or otherwise already existing that is ongoing in nature will be reviewed
by the audit committee annually to ensure that such related person transaction has been conducted in accordance with the previous approval granted by the audit committee, if any, and that all required
disclosures regarding the related person transaction are made. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that transactions involving compensation of executive officers will be reviewed and approved by our compensation committee in the manner to be specified in the
charter of the compensation committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
related person transaction reviewed under this policy will be considered approved or ratified if it is authorized by the audit committee in accordance with the standards set forth in
the policy after full disclosure of the related person's interests in the transaction. As appropriate for the circumstances, the policy provides that the audit committee will review and
consider:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person's interest in the related person transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount involved in the related person transaction; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount of the related person's interest in the transaction without regard to the amount of any
profit or loss; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction was undertaken in the ordinary course of business of our company; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to us than the
terms that could have been reached with an unrelated third party; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purpose of, and the potential benefits to us of, the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other information regarding the related person transaction or the related person in the context of the proposed transaction that
would be material to investors in light of the circumstances of the particular transaction. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>The
policy provides that the audit committee will review all relevant information available to it about the related person transaction. The policy provides that the audit committee may approve or
ratify the related person transaction only if the audit committee determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests. The policy
provides that the audit committee may, in its sole discretion, impose such conditions as it deems appropriate on us or the related person in connection with approval of the related person transaction. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=33,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=846650,FOLIO='29',FILE='DISK128:[16ZBB1.16ZBB71401]DI71401A.;4',USER='HYUNG',CD='26-APR-2016;11:05' -->
<A NAME="page_di71401_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di71401_proposal_no._2_#151;ratificati__pro06343"> </A>
<A NAME="toc_di71401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2&#151;RATIFICATION OF THE APPOINTMENT OF ERNST&nbsp;&amp; YOUNG&nbsp;LLP AS CATABASIS'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL  YEAR ENDING DECEMBER 31, 2016    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stockholders are being asked to ratify the appointment by the audit committee of the Board of Directors of Ernst&nbsp;&amp;
Young&nbsp;LLP as our independent registered public accounting firm. Ernst&nbsp;&amp; Young&nbsp;LLP has served as the company's independent registered public accounting firm since 2010. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee is solely responsible for selecting our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2016. Stockholder approval is not
required to appoint Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm. However, the Board of Directors believes that submitting the appointment of Ernst&nbsp;&amp;
Young&nbsp;LLP to the stockholders for ratification is good corporate governance. If the stockholders do not ratify this appointment, the audit committee will reconsider whether to retain
Ernst&nbsp;&amp; Young&nbsp;LLP. If the selection of Ernst&nbsp;&amp; Young&nbsp;LLP is ratified, the audit committee, in its discretion, may direct the appointment of a different independent
registered public accounting firm at any time it decides that such a change would be in the best interest of Catabasis and its stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
representative of Ernst&nbsp;&amp; Young&nbsp;LLP is expected to be present at the Annual Meeting and will have an opportunity to make a statement if he or she desires to do so and to
respond to appropriate questions from our stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the fees Ernst&nbsp;&amp; Young&nbsp;LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,082,688</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,440</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,091,688</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,440 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit
fees consist of fees billed for professional services performed by Ernst&nbsp;&amp; Young&nbsp;LLP for the audit of our annual consolidated financial
statements, the review of interim consolidated financial statements, and related services that are normally provided in connection with registration statements, including the registration statement
for our initial public offering.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit-related
fees may consist of fees billed by an independent registered public accounting firm for assurance and related services that are reasonably
related to the performance of the audit or review of our consolidated financial statements. There were no such fees incurred in 2015 or 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Tax
fees may consist of fees for professional services, including tax consulting and compliance performed by an independent registered public accounting
firm.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>There
were no such fees incurred in 2015 or 2014  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
such accountant services and fees for 2015 were pre-approved by our audit committee in accordance with the "Pre-Approval Policies and Procedures" described below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=34,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=473386,FOLIO='30',FILE='DISK128:[16ZBB1.16ZBB71401]DI71401A.;4',USER='HYUNG',CD='26-APR-2016;11:05' -->
<A NAME="page_di71401_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pre-approval Policy and Procedures  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our IPO in June 2015, the audit committee of our Board of Directors adopted policies and procedures for the
pre-approval of audit and non-audit services for the purpose of maintaining the independence of our independent auditor. We may not engage our independent auditor to render any audit or non-audit
service unless either the service is approved in advance by the audit committee, or the engagement to render the service is entered into pursuant to the audit committee's pre-approval policies and
procedures. Notwithstanding the foregoing, pre-approval is not required with respect to the provision of services, other than audit, review or attest services, by the independent auditor if the
aggregate amount of all such services is no more than 5% of the total amount paid by us to the independent auditor during the fiscal year in which the services are provided, such services were not
recognized by us at the time of the engagement to be non-audit services and such services are promptly brought to the attention of the audit committee and approved prior to completion of the audit by
the audit committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, our audit committee may pre-approve services that are expected to be provided to us by the independent auditor during the following 12&nbsp;months. At the time such
pre-approval is granted, the audit committee must identify the particular pre-approved services in a sufficient level of detail so that our management will not be called upon to make a judgment as to
whether a proposed service fits within the pre-approved services and, at each regularly scheduled meeting of the audit committee following such approval, management or the independent auditor shall
report to the audit committee regarding each service actually provided to us pursuant to such pre-approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
our 2015 fiscal year, no services were provided to us by Ernst&nbsp;&amp; Young&nbsp;LLP or any other accounting firm other than in accordance with the pre-approval policies and
procedures described above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE RATIFICATION OF ERNST&nbsp;&amp;
YOUNG&nbsp;LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=35,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=85382,FOLIO='31',FILE='DISK128:[16ZBB1.16ZBB71401]DI71401A.;4',USER='HYUNG',CD='26-APR-2016;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk71401_1_32"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71401_principal_stockholders"> </A>
<A NAME="toc_dk71401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the
beneficial ownership of our common stock as of March&nbsp;15, 2016 by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors and our director nominees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our NEOs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our current directors and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole
or shared voting power or investment power with respect to those securities and include shares of common stock issuable upon the exercise of stock options that are immediately exercisable or
exercisable within 60&nbsp;days after March&nbsp;15, 2016. Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole
voting and investment power with respect to the shares beneficially owned by them, subject to community property laws, where applicable. The information is not necessarily indicative of beneficial
ownership for any other purpose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage ownership calculations for beneficial ownership are based on 15,346,337 shares of common stock outstanding as of March&nbsp;15, 2016. Except as otherwise indicated in
the table below, addresses of named beneficial owners are in care of Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA&nbsp;02139. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to
options held by that person that are currently exercisable or exercisable within 60&nbsp;days after March&nbsp;15, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=36,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=552630,FOLIO='32',FILE='DISK128:[16ZBB1.16ZBB71401]DK71401A.;9',USER='HYUNG',CD='26-APR-2016;11:29' -->
<A NAME="page_dk71401_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>2016.
We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:93pt;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,93pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5% Stockholders</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with SV Life Sciences(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,857,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarus Lifesciences II,&nbsp;L.P.(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,752,488</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MedImmune Ventures,&nbsp;Inc.(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,632,652</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FRM&nbsp;LLC(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,457,298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced Technology Ventures VIII,&nbsp;L.P.(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,133,943</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Camber Capital Management,&nbsp;LLC(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>NEOs and Directors</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>460,134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rick Modi(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42,673</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne Donovan, Ph.D., M.D.(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>93,036</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,765</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,752,488</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,890,852</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Jirousek, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>436,150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ron Laufer, M.D.(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,632,652</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,857,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>All current executive officers and directors as a group (11 persons)(15)</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,171,417</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than 1% of our outstanding stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 2,798,528 shares of record held by SV Life Sciences Fund V,&nbsp;L.P. ("SVLS&nbsp;V&nbsp;LP") and 59,139 shares of record held by SV Life
Sciences Fund V Strategic Partners,&nbsp;L.P. ("SVLS&nbsp;V SPP"). SV Life Sciences Fund V (GP),&nbsp;LP ("SVLS&nbsp;V&nbsp;GP") is the general partner of SVLS&nbsp;V&nbsp;LP and
SVLS&nbsp;V SPP. The general partner of SVLS&nbsp;V&nbsp;GP is SVLSF&nbsp;V,&nbsp;LLC. The members of the investment committee of SVLSF&nbsp;V,&nbsp;LLC are Kate Bingham, James Garvey,
Eugene D. Hill, III, David Milne and Michael Ross, a member of our Board of Directors. SVLS&nbsp;V&nbsp;GP, SVLSF&nbsp;V,&nbsp;LLC and each of the individuals comprising the
SVLSF&nbsp;V,&nbsp;LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS&nbsp;V&nbsp;LP and SVLS&nbsp;V SPP. Each of
SVLS&nbsp;V&nbsp;GP, SVLSF&nbsp;V,&nbsp;LLC and the individual members of the SVLSF&nbsp;V,&nbsp;LLC investment committee disclaim beneficial ownership of the shares owned directly by
SVLS&nbsp;V&nbsp;LP and SVLS&nbsp;V SPP except to the extent of any pecuniary interest therein. The address for the entities is One Boston Place, Suite&nbsp;3900, 201 Washington Street,
Boston, Massachusetts 02108. The information about SVLS&nbsp;V&nbsp;LP and SVLS&nbsp;V SPP is based upon a Schedule&nbsp;13D filed with the SEC on July&nbsp;8, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 2,752,488 shares held of record by Clarus Lifesciences II,&nbsp;L.P. ("Clarus"). Clarus Ventures II&nbsp;GP,&nbsp;L.P. (the "GPLP"), as
the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The&nbsp;GPLP disclaims beneficial ownership of all shares held of record by
Clarus in which the&nbsp;GPLP does not have an actual pecuniary interest. Clarus Ventures II,&nbsp;LLC (the "GPLLC"), as the sole general partner of the&nbsp;GPLP, may be deemed to beneficially
own certain of the shares held of record by Clarus. The&nbsp;GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=37,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=903561,FOLIO='33',FILE='DISK128:[16ZBB1.16ZBB71401]DK71401A.;9',USER='HYUNG',CD='26-APR-2016;11:29' -->
<A NAME="page_dk71401_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>not
have an actual pecuniary interest. Each of Nicholas Galakatos, a member of our Board of Directors, and Dennis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, as
individual Managing Directors of the&nbsp;GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs.&nbsp;Galakatos, Henner, Liptak, Simon, Steinmetz
and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. The address for the entities is 101 Main Street,
Suite&nbsp;1210, Cambridge, MA&nbsp;02142. The information about Clarus share ownership is based on a Schedule&nbsp;13D filed with the SEC on February&nbsp;19, 2016 and is as of
December&nbsp;31, 2015.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ron
Laufer, a member of our Board of Directors, is the Senior Managing Partner of MedImmune Ventures,&nbsp;Inc., and as a result, Dr.&nbsp;Laufer may be
deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures,&nbsp;Inc. Dr.&nbsp;Laufer disclaims beneficial ownership of such shares except to the extent of
any pecuniary interest therein. The address of MedImmune Ventures,&nbsp;Inc. is 1 MedImmune Way, Gaithersburg, Maryland 20878.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>FMR&nbsp;LLC
and Abigail P. Johnson filed a joint Amendment No.&nbsp;1 to Schedule&nbsp;13G with the SEC on February&nbsp;12, 2106 indicating
beneficial ownership of 1,457,298 shares of our common stock, of which they held sole power to vote or direct the vote with respect to 25,707 shares and sole power to dispose or direct the disposition
of 1,457,298 shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ATV
Associates&nbsp;VIII,&nbsp;LLC ("ATV A&nbsp;VIII") is the General Partner of Advanced Technology Ventures&nbsp;VIII,&nbsp;L.P.
("ATV&nbsp;VIII") and exercises voting and dispositive authority over the shares held by ATV&nbsp;VIII. Voting and dispositive decisions of ATV A&nbsp;VIII are made collectively by Michael A.
Carusi, Jean George, a member of our Board of Directors, Steven N. Baloff, Robert C. Hower and William C. Wiberg (collectively, the "ATV&nbsp;VIII Managing Directors"). ATV A&nbsp;VIII and the
ATV&nbsp;VIII Managing Directors disclaim beneficial ownership of the shares held by ATV&nbsp;VIII except to the extent of their pecuniary interest therein. The address for the entities is
500&nbsp;Boylston Street, Suite&nbsp;1380, Boston, MA&nbsp;02116. The information about ATV&nbsp;VIII share ownership is based on a Schedule&nbsp;13G filed with the SEC on
February&nbsp;16, 2016 and is as of December&nbsp;31, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Camber
Capital Management&nbsp;LLC and Stephen Dubois filed a joint Amendment No.&nbsp;1 to Schedule&nbsp;13G with the SEC on February&nbsp;12, 2016
indicating that they have shared voting power and shared dispositive power with respect to 1,000,000 shares of our common stock. Information is based on such Amendment No.&nbsp;1 to
Schedule&nbsp;13G and is as of December&nbsp;30, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;197,509 shares of common stock issuable upon the exercise of options and (ii)&nbsp;8,753 shares of common stock issuable upon the
exercise of warrants, in each case exercisable within 60&nbsp;days after March&nbsp;15, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
38,579 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;15, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
92,627 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;15, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 5,765 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after March&nbsp;15, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in note&nbsp;(2) above. Dr.&nbsp;Galakatos is a Managing Director of Clarus Ventures II,&nbsp;LLC, which the sole
general partner of the&nbsp;GPLP, which is the sole general partner of Clarus, and, as a result, Dr.&nbsp;Galakatos shares investment and voting control over the shares held by Clarus.
Dr.&nbsp;Galakatos disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Dr.&nbsp;Galakatos' address is 101 Main Street, Suite&nbsp;1210,
Cambridge, MA&nbsp;02142. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=38,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=747363,FOLIO='34',FILE='DISK128:[16ZBB1.16ZBB71401]DK71401A.;9',USER='HYUNG',CD='26-APR-2016;11:29' -->
<A NAME="page_dk71401_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in note&nbsp;(5) above and 666,145 shares of common stock held by Lightstone Ventures,&nbsp;L.P. and 90,764 shares of
common stock held by Lightstone Ventures (A),&nbsp;L.P. Ms.&nbsp;George is an ATV III Managing Director and, as a result, shares voting and dispositive power over the shares held by Advanced
Technology Ventures VIII,&nbsp;L.P. LSV Associates,&nbsp;LLC ("LSV&nbsp;GP") is the General Partner of Lightstone Ventures,&nbsp;L.P. and Lightstone Ventures (A),&nbsp;L.P. (collectively,
"LSV") and exercises voting and dispositive authority over the shares held by LSV. Voting and dispositive decisions of LSV&nbsp;GP are made collectively by Michael A. Carusi, Jean George, a member
of our Board of Directors, Ralph E. Christoffersen and Henry A. Plain, Jr. (collectively, the "LSV Managing Directors"). LSV&nbsp;GP and the LSV Managing Directors disclaim beneficial ownership of
the shares held by LSV except to the extent of their pecuniary interest therein. Ms.&nbsp;George disclaims beneficial ownership of the shares held by ATV VIII and LSV except to the extent of any
pecuniary interest therein. Ms.&nbsp;George's address is 500 Boylston Street, Suite&nbsp;1380, Boston, MA&nbsp;02116.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in note&nbsp;(3) above. Dr.&nbsp;Laufer is the Senior Managing Partner of MedImmune Ventures,&nbsp;Inc., and as a
result, Dr.&nbsp;Laufer may be deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures,&nbsp;Inc. Dr.&nbsp;Laufer disclaims beneficial ownership of
such shares except to the extent of any pecuniary interest therein. Dr.&nbsp;Laufer's address is c/o MedImmune Ventures, 1 MedImmune Way, Gaithersburg, Maryland 20878.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in note&nbsp;(1) above. Dr.&nbsp;Ross is a member of the investment committee of SVLSF V,&nbsp;LLC, which is the
general partner of SV Life Sciences Fund V (GP), which is the general partner of SV Life Sciences Fund V,&nbsp;L.P. and SV Life Sciences Fund V Strategic Partners,&nbsp;L.P., and, as a result,
Dr.&nbsp;Ross may be deemed to share voting, dispositive and investment power over the shares held of record by SV Life Sciences Fund V,&nbsp;L.P. and SV Life Sciences Fund V Strategic
Partners&nbsp;L.P. Dr.&nbsp;Ross disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Dr.&nbsp;Ross' address is One Boston Place,
Suite&nbsp;3900, Boston, Massachusetts 02108.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;515,784 shares of common stock issuable upon the exercise of options and (ii)&nbsp;17,506 shares of common stock issuable upon the
exercise of warrants, in each case exercisable within 60&nbsp;days after March&nbsp;15, 2016.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71401_section_16(a)_benefici__dk702027"> </A>
<A NAME="toc_dk71401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers, and persons holding more than 10% of Catabasis
common stock to report their initial ownership of our common stock and other equity securities and any changes in that ownership in reports that must be filed with the SEC. The SEC has designated
specific deadlines for these reports, and we must identify in this proxy statement those persons who did not file these reports when due. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
solely on a review of reports furnished to us, or written representations from reporting persons, we believe all directors, executive officers, and 10% owners timely filed all
reports regarding transactions in Catabasis's securities required to be filed for 2015 by Section&nbsp;16(a) under the Exchange Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=39,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=588887,FOLIO='35',FILE='DISK128:[16ZBB1.16ZBB71401]DK71401A.;9',USER='HYUNG',CD='26-APR-2016;11:29' -->
<A NAME="page_dk71401_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71401_report_of_the_audit_committee"> </A>
<A NAME="toc_dk71401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The audit committee is appointed by the Board of Directors to assist the Board of Directors in fulfilling its oversight
responsibilities with respect to (1)&nbsp;the integrity of our financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance
with legal and regulatory requirements, (2)&nbsp;the qualifications, independence, and performance of our independent registered public accounting firm, (3)&nbsp;the performance of our
internal audit function, if any, and (4)&nbsp;other matters as set forth in the charter of the audit committee approved by the Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management
is responsible for the preparation of the Catabasis financial statements and the financial reporting process, including its system of internal control over financial reporting
and its disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an audit of the Catabasis financial statements in accordance with the
standards of the Public Company Accounting Oversight Board, or PCAOB, and issuing a report thereon. The audit committee's responsibility is to monitor and oversee these processes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with these responsibilities, the audit committee reviewed and discussed with management and the independent registered public accounting firm the audited consolidated
financial statements of Catabasis for the fiscal year ended December&nbsp;31, 2015. The audit committee also discussed with the independent registered public accounting firm the matters required to
be discussed by the PCAOB's Auditing Standard No.&nbsp;16, </FONT><FONT SIZE=2><I>Communication with Audit Committees</I></FONT><FONT SIZE=2>. In addition, the audit committee received written
communications from the independent registered public accounting firm confirming its independence as required by the applicable requirements of the PCAOB and has discussed with the independent
registered public accounting firm its independence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the reviews and discussions referred to above, the audit committee recommended to the Board of Directors that the audited consolidated financial statements of Catabasis be
included in its Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2015, that was filed with the SEC. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF CATABASIS PHARMACEUTICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Kenneth Bate, Chairman<BR>
Michael Ross, Ph. D.<BR>
Ron Laufer, M.D.<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=40,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=944498,FOLIO='36',FILE='DISK128:[16ZBB1.16ZBB71401]DK71401A.;9',USER='HYUNG',CD='26-APR-2016;11:29' -->
<A NAME="page_dk71401_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71401_householding"> </A>
<A NAME="toc_dk71401_4"> </A>
<BR></FONT><FONT SIZE=2><B>  HOUSEHOLDING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some banks, brokers and other nominee record holders may be participating in the practice of "householding" proxy statements and annual
reports. This means that only one copy of our documents, including the annual report to stockholders and proxy statement, may have been made available to multiple stockholders in your household. We
will promptly deliver a separate copy of either document to you upon written or oral request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building&nbsp;1400E, Suite B14202,
Cambridge, MA&nbsp;02139, Attention: Corporate Secretary, or telephone: (617)&nbsp;349-1971. If you want to receive separate copies of the proxy statement or annual report to stockholders in the
future, or if you are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the
above address and phone number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71401_stockholder_proposals"> </A>
<A NAME="toc_dk71401_5"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stockholder who would like to have a proposal considered for inclusion in our 2017 proxy statement must submit the proposal in
accordance with the procedures outlined in Rule&nbsp;14a-8 of the Exchange Act so that it is received by us no later than December&nbsp;27, 2016, which is 120&nbsp;days prior to the first
anniversary of the mailing date of this proxy statement. However, if the date of the 2017 annual meeting of stockholders is changed by more than 30&nbsp;days from the date of this year's meeting,
then the deadline is a reasonable time before we begin to print and send our proxy statement for the 2017 annual meeting of stockholders. SEC rules set standards for eligibility and specify the types
of stockholder proposals that may be excluded from a proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a stockholder wishes to propose a nomination of persons for election to our Board of Directors or present a proposal at an annual meeting but does not wish to have the proposal
considered for inclusion in our proxy statement and proxy card, our amended and restated bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual
meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Board of Directors or by a stockholder of record on
the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder's intention to bring such
business before the meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the
first anniversary of the preceding year's annual meeting. However, in the event that the date of the annual meeting is advanced by more than 20&nbsp;days, or delayed by more than 60&nbsp;days,
from the first anniversary of the preceding year's annual meeting, a stockholder's notice must be so received no earlier than the 120th&nbsp;day prior to such annual meeting and not later than the
close of business on the later of (A)&nbsp;the 90th&nbsp;day prior to such annual meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting was
mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2017 Annual Meeting of Stockholders, the required
notice must be received by our corporate secretary at our principal executive offices no earlier than February&nbsp;15, 2017 and no later than March&nbsp;17, 2017. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
proposals should be addressed to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA&nbsp;02139, Attention: Corporate
Secretary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=41,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=744071,FOLIO='37',FILE='DISK128:[16ZBB1.16ZBB71401]DK71401A.;9',USER='HYUNG',CD='26-APR-2016;11:29' -->
<A NAME="page_dk71401_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71401_other_matters"> </A>
<A NAME="toc_dk71401_6"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned
in this proxy statement are properly brought before the meeting, the individuals named in the proxy made available to stockholders intend to use their discretionary voting authority under the proxy to
vote the proxy in accordance with their best judgment on those matters. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><BR>
<FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=42,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=943352,FOLIO='38',FILE='DISK128:[16ZBB1.16ZBB71401]DK71401A.;9',USER='HYUNG',CD='26-APR-2016;11:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET - www.proxyvote.com Use the Internet to transmit your voting   instructions and for electronic delivery of information up until 11:59 P.M.   Eastern Time the day before the cut-off date or meeting date. Have your proxy   card in hand when you access the web site and follow the instructions to   obtain your records and to create an electronic voting instruction form.   CATABASIS PHARMACEUTICALS, INC. One Kendall Square, Building 1400E Suite   B14202 Cambridge, MA 02139 ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If   you would like to reduce the costs incurred by our company in mailing proxy   materials, you can consent to receiving all future proxy statements, proxy   cards and annual reports electronically via e-mail or the Internet. To sign   up for electronic delivery, please follow the instructions above to vote   using the Internet and, when prompted, indicate that you agree to receive or   access proxy materials electronically in future years. VOTE BY PHONE -   1-800-690-6903 Use any touch-tone telephone to transmit your voting   instructions up until 11:59 P.M. Eastern Time the day before the cut-off date   or meeting date. Have your proxy card in hand when you call and then follow   the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return   it in the postage-paid envelope we have provided or return it to Vote   Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE,   MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR   RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY   WHEN SIGNED AND DATED. For Withhold For All Except To withhold authority to   vote for any individual nominee(s), mark &#147;For All Except&#148; and write the   number(s) of the AllAll The Board of Directors recommends you vote FOR the   following: nominee(s) on the line below. 0 0 0 1. Election of Directors   Nominees 1a Jill C. Milne, Ph. D. 1b Michael D. Kishbauch The Board of   Directors recommends you vote FOR the following proposal: 2. Ratification of   the appointment of Ernst &amp; Young LLP as our independent registered public   accounting firm for the fiscal year ending December 31, 2016. NOTE: The   shares represented by this proxy when properly executed will be voted in the   manner directed herein by the undersigned stockholder(s). If no direction is   made, this proxy will be voted FOR the election of the nominees listed in   item 1 and FOR item 2. If any other matters properly come before the meeting,   or if cumulative voting is required, the persons named in this proxy will   vote in their discretion. ForAgainst Abstain 0 0 0 Please sign exactly as   your name(s) appear(s) hereon. When signing as attorney, executor,   administrator, or other fiduciary, please give full title as such. Joint   owners should each sign personally. All holders must sign. If a corporation   or partnership, please sign in full corporate or partnership name, by   authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint   Owners) Date 0000289936_1 R1.0.1.25 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="680" height="880" src="g93142bgi001.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=43,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=353324,FOLIO='',FILE="DISK129:[16ZBB2.16ZBB71402]9314-2-BG_ZBB71402.CHC",USER="HYUNG",CD='Apr 26 11:27 2016' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting:   The Notice and Proxy Statement, Annual Report and Form 10-K are available at   www.proxyvote.com . THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF   DIRECTORS OF CATABASIS PHARMACEUTICALS, INC. June 15, 2016 The stockholder(s)   hereby appoint(s) Jill C. Milne, Ph. D., and Deirdre A. Cunnane, or either of   them, as proxies, each with the power to appoint her substitute, and hereby   authorize(s) them to represent and to vote, as designated on the reverse side   of this ballot, all of the shares of Common Stock of Catabasis   Pharmaceuticals, Inc. that the stockholder(s) is/are entitled to vote at the   Annual Meeting of Stockholders to be held at 10:00 a.m., Eastern Time, on   June 15, 2016, at the offices of WilmerHale located at 60 State Street,   Boston, MA 02109, and any adjournment or postponement thereof. THIS PROXY,   WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE STOCKHOLDER(S). IF   NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED FOR THE ELECTION OF THE   NOMINEES LISTED ON THE REVERSE SIDE FOR THE BOARD OF DIRECTORS, AND FOR   PROPOSAL 2. IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE UPON SUCH   OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY POSTPONEMENT OR   ADJOURNMENT THEREOF. PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD   PROMPTLY USING THE ENCLOSED REPLY ENVELOPE. Continued and to be signed on   reverse side 0000289936_2 R1.0.1.25 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="680" height="880" src="g93142bgi002.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=44,EFW="2228428",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=265570,FOLIO='',FILE="DISK129:[16ZBB2.16ZBB71402]9314-2-BG_ZBB71402.CHC",USER="HYUNG",CD='Apr 26 11:27 2016' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g890909.jpg
<DESCRIPTION>G890909.JPG
<TEXT>
begin 644 g890909.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@!)35),3%]'4D%02$E#4SI;0T%404)!
M4TE37U!(05)-04-%551)0T%,4U])3D-=0T%404)!4TE37U1!1U\T0U],5%)(
M1"Y%4%/_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" !1 J0# 2(  A$! Q$!_\0 'P !  (" P$! 0$
M      @)!PH!!08$ P(+_\0 -A    8#  $# P,"! 4%     @,$!08'  $(
M"1$2$Q05(0H6,2)!%R-181@RH;'P)"53<9'_Q  = 0$  @(# 0$
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M4 R@Q2_I&MQ8KL96=+N+S(QRB%KPQ 664V%O*Q-H4SCZ9%K>PHF:9L9A<OB
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..1,8QA$QC&$3&,81?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g102608.jpg
<DESCRIPTION>G102608.JPG
<TEXT>
begin 644 g102608.jpg
M_]C_X  02D9)1@ ! 0$!&@$:  #__@!%35),3%]'4D%02$E#4SI;0T%404)!
M4TE37U!(05)-04-%551)0T%,4U])3D-=2DE,3%]#7TU)3$Y%7TM?4TE'+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( $, E $!$0#_Q  =  $
M @,! 0$!            " D!!@<* @0%_\0 +A   00#  (! P,$ P #
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MOJIGZ\::XVS\[8UQC.,8T"M;GJ^X7%DM:RF8B9*U#9TAIFQLALNE4(O9\3'
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M>/6:#9]A-3+557&FV<19[)[AJGBN-10E.(]95D36P7DF;UW3M,19M,;2F[.
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M#@9!FYT>#B(F WE9EAP5B2$/$TW00BC&\/@J^F%1:[3?'U>608QC7'QC\?\
MN<Y_WG/SG/\ O/F?&<8SC.,X^<9_;.,_C./\9\>/'CQX\>/*H;\D4O[=Z7F?
M!=?2>0P*@J/!5U*N\+%AYX[$)],%[-9NI37/'E=R<(X#GH?B>0E@WGW05@QL
MLWD(2J#\4KZ)NAYNT"<ABEE=>5U ZDA$6K6L(=&:^KZ$!64<B$*AH0?'(M&0
M(U+"+$0"!BD&P\8/:IX^$FS5!-/&<[;[?4KOOOMN?E2_9PO;ECJOF3OB'_TP
M**S><07B[MK&$FC(-(*:MXZ\!\\6I*'ZFGPB=HCH\]%(R&-K?3AK7]UV .(.
M=!R++9G;/KGZM<9_;Y_&<8S\_&V/VVQ\_P#6<9Q_[CS/CQX\>/'CQX\>/'CR
ML*W*>Z8YNONQ.K^0HL%O>,WDYAQ+J3DZ02:.5W+95)()#@E= ;JYRLPV-0C2
M%L:5_&8U#I15=OR"/UG8(F.1\D+L2KY(+)+R_JE(^QKE*ZR^\%WG^],W<PU3
MQ(N<.CQBU#= QM?;;&FV'%9V$J*(R,5]S9/1K,*_=3."&-5F[@'*2;9PBMO.
M--PBKIHJEO\ =24TU4352UV534TWUQOINFHGKMIOIOKMC;3?3;;7;7.-M<YQ
MGY\IX]O$LA%V4^.]<L0.L)1TCUU/:8C@>M0&1LAD\-J*/7-7\ZN.]YV$PHNO
M#*TKJNXN?>:30^W8LW\S<Q:*1EP]EAL2RWN+TQG&/W_G;?/^MML[8_/[X_;.
M/V_C\>?7CQX\>/'CQX\>/'CQYQ.ZN<^?>CP@^)="T;45Z1<<\R4&QZWZXB%D
M!QA+33Z-2 P=, YAJ.?8T^=,.V22"_T9VT^Y].V<9@ZOZ9_7'EXS:#Z(D<9
MCU5WPZ$P?H?IN UN-</]MM7N!M90FY %?#F[M)JT:N&;*,H,U631HPW0RS:M
MT$Y7<X\8<H\ALR8OFCGZK:9P>10Q)"T+B@YC*I7EIG35IO+YFNFYETN4;8UQ
?ENK)#911';YW3VUVVSG,H/'CQX\>/'CQX\>/'CS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g93142bgi001.gif
<DESCRIPTION>G93142BGI001.GIF
<TEXT>
begin 644 g93142bgi001.gif
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M7#G!!$+P#158""!T^=O;8>3APDSXF4!2AX-;F"*UV AQ'B*Q#U.TPK*M@*+
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M?U>G3#AM!] PH%[@,'GDTT]Z"W9K!-B:63)07LR UJ%37L( TT8@4_Z5:G9
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MAD-(,0IC'UTM.&&'??"!#Q"1.]T1PG9?E(<0J! 8W.T.!V$DM[EP@+O7P0Y
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M*RHC115['V7L"%04!T^D*D]$'T$K1Q0+-F7,.B:LET/ A-'ZB[F+OOM2#A+
M@G7PA4;^N"]3N**+(X16P %H, 4[H+O7>@BK<!=1,XM%:P,<  5"$ 8JX ;
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MA .82C[X8ILS!1(PI*G$ADNP6@\8A!F9AR6X&2R&+'%P6Q*0/Q+8U\.YR8[
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MA' J$A]&I0JK5VRP.6JQK9(D'"?^"!6?J;A!1K BB'QBYAB)!*'JL'-D&'4
MJPS;)&.LL! #IN8>ME_Z(QCKB%WU,(L(\5[YQ5O<519#134?DSBW[_O& E@0
M@;Y1D&7&N;]2 V8@G(TX" 6CAOL +?%), 5S"IMM@17-%U#PT$BX<T*(;Y&
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MP5(K<'"B[R"M)!;/(=RTXD6EMR6&"A.'$"\$%I!SO\_R\ID212-TEKP!$K"
M!CP@ A.HP 4R\#'SJ%<\4O3 >CV000&[8,P($8E6Y"2"#&J$UH3$( \R2#$5
MG"#L*EB1!K*PA=J9QRW@YK/<4:06,D2@+U;F,V9H)X?KXN%DA $-R.D$%+G)
MB_',Y4.8".-,E.%&$N>V1!=2,7GD<.+.JJC%+8X+&LJ@!C."% ]A# ,;H)H'
M078(BEK$PQ?"4 <6J*&,6SB,(M!X(#3:&*0\)DU(RG@/.6ZAC'5 8QC*")@>
M<49'0OK^8B)SQ)8AYX$-9N20"H2AB!WLX#-?"#!;S! '-^BH2$B&BA/.PADH
M8"%'8<0C'L-@AM;F,0Q?K*,-'!$@*DC ![Q ! ODX"4YPIA(F$PR5-A0!BAC
MB(V#02-(ZY@(1>8H#DON8Y;5,44UW[,.9@Q#'&]4Y-0H20U04*%:HDR,%_>H
M#'5 @Y74D)DX\C@/&JKC%F,98KZ4L4QAB.$6V*@%%KDHT($2M* -C,<2F!"%
M,BQ!'&ZS 1]4  O_1 $:2Q"#'2[A-AEP!!4VH(+V*$(28<!A$#_RA1?$<8F7
M4 1"45!&([Q@@U;@0 R@@HE)O<",*##!(2W@4"L^&@E4W$3^&&U80A3:L(-#
MP,0+8A#,$@@!$S48P114B (?N,'3H18U#W!0T%4BP00L5/5%.+@$3'Q1!AP,
M @Z $^ A9-!6C91!".73""=:< B31N%,5*WJ4?_'A*1T"11EX 8G4#>,CPYB
M!XWPA1IPH-1#H"(_PQ!&"_H&(W'P=!"^^"D3X""$6PAU?4@UPJ^\(*6H-J(1
M;6"&WDA*D74PU Z-6H(7(F$#3*B!"BT 19C@8-#A$K>XQDV=0)2Q'"IHJPPR
M\ DTPG36M%3/=#;PB5I-HQC#\0$3\CD$(;# #>I-%18&XT,96H )*ER(B/&@
M0AYK489U4,%TZ\!"=I%R$SN Q'#^38$)]2Z1G')21 VP\(4*;&I8II4A4UYE
M'"S4<(A#Q#$2X<7&(5BZCU;4=22 JQ=4,O*5IXC8=/&0[I5B4@L6]7>^:6'*
M/#@QB#*\!V=EL,-'-M-AK%!5/[<H ^6D@V";QBH>&]'*C:&IDRA08\(5)@0V
MJ" .)KR$NY?$1A0&UJTH+ &\6E6'MT(3Q>.2N<QF/C-D+'*6LU"#"3$-K[7:
M,(A:&"42AXA")+P@%&&@ @M\*)J0TAME5*@A$O@]'4S@<(A:"$,(P.6(7XC8
MH#76(@JW8 (G1,QG/_,M6$WQK_HH8F=.J $55*B7&GRQV+W"8B DI8*G;Q$)
M'-3B$D+^42F%48'H MLA-&UX*T6<@M+1\+868B!V1GKJ69B48<+\O84P+"VG
M,HBA8C<1H$/]W(96M*'75X%%ITVQ-ZC 01C7'<12Z'*)P_:Y2.I"**$-+0[>
MFMH76(#6/-)+'G$LX1:RODC](D&.?B^A%>4[-9H3KO"%%W<>6<WJ(%35MZ4P
M.@IY$ <?R,&]1DQ\$,/P0A10P0RFPH3#^[@T=3CNA5#S#PM>@(8=O@>+0?"J
MQB>/ AS(X1]0#.-U'@<Y*JCA!35@HQ'*8(:=M8<*.(BC#4SXG='G08B0Q\,_
MJ,#&T+$1"65P8Q#Q0 4H"*%Q5-A;"!HVM1BFUPJO1S,2XG#^:AE@(09EP%U^
MMZ "'QRF!B;\).H[YQXJU$<(J>8%Z!E&>R,T*'2B#V/KCI<Z%5#1\WD,0N[,
M /K(A02B\42<'$Z_Q27N$RJ3?ZG+PZ#"C4&A/D[T;6]1(#G#8R_[V3?P@D*2
M(.Y+J"<)CG ?Y* A-!PDPMMS[(0>%)X*.UG"F-T^,2K44^^AKQ,A"?"$BX%@
MEXP B_7QOO@6[/[S+9BY6@Q_A12\112 2'W=3W#YWH>@\Y>/M-R]%YJVYWWP
M63[][SL_][3_/P &8)DQ R@HG\()0R-L7[DT463<@@*RC@U%!@$:H !6H 5>
M8 +%PPU=1PAQH&1,#6, FF/0"V/^M$QD@&!WA$UEM!(*.@;$L(SPA& =[0PV
M>$0'EB %8L?18" /]J /9L?QJ= \8$**P400XA[O&>&[J('R)5_S[5^Z'-8*
M75^*<()P.*$OG,<)(2&O0,WZ\8%(+$@*440KD%_X2=_NL9_.< *+&" )A1\1
M@@(FI*%B5$COY0'D""$*35\6,D:EM4!;3*$)Z0PF!,D6CB$=ZHG3W9'__: C
M/J(/^H(84($PV($8T(HPA(B&482I>4&WB,&Q4=NQT5PC#$.?B8&]*5],3103
MM (S8 $5<$+5+0$HT!T6;(#SA);(D /?(%TD9"(<K(,OX!P<V, MZ%FE:84E
M4D$68H/^U2%%%)3/>N5!#1)"P, "-D5"'J""]["$8G!"_<"$3[1!>(F#>(1<
M(Y@"%B@?-0Q*T7D!$5$$%6!!(PC!Z_$BK2B&&LC:)5Z"#0P"UJ64]?B$%]3&
MBZR=#,S@PU14E, (QW #T)4B*&"!&,C7]SB1T<%43/T$.GF 0R25.-A!&= 0
M)):D2=(>D:C (;3B(.3:KNG$CI  )PC!,,@%3<I%7VS;)=B!3/9%YA ":=E!
M%)C"$OC"$I@"$UP:)RP!,R0$%K2!+"9&1*B!&C3"G:G!$O19=!C6+2R!<L0;
M$Z!"2XH!)T2!&]U"8XT$1[06)L">S[R<WPP5'[3 )HH##MC^@:;<@G@0@AA$
M0C^A)0YXF!<HGZ(]CQH0@O+!1224@;U%@A"H01DH1E-(F$B( ;@-RB%(&"PP
M92S:@%"Z16,T"#>(@Q%<6A0I PX<@N& XZ5%!#_%8TSX@N%(V"$(U\X\7>05
M6EC&X$GVIF\VG!?$G%",%X5A6$CQFW]XEU\HIRVMHQB  K"TQ3IFCFRJ %4:
M%GU=@AK0UUPP%\R5@?+IEAKD 7@M@<M957P]A1HT2),-IX7)11DP#1\$IUIV
M!%F%BI[ 01E0SR'<F!>$%#;\5&Z56E.0F"\, D9=!;#!!$C4 E/ YCXTPI*X
MG1?$E>)P3*IAA7]1#DHTA&R66 O^M$$9T$1CO!<W:!5MP68\K,32K9<ZJ %S
MPF93L!@LU +F&"%:8)A03,AO]JB/#I=&>$%JB@$W;,M*GE5B#)QS<<)@PH%;
MS ,<0*<8R !2+JD8*!]6<%;:U4)FE0'G#!:XS4/!V0$5"$$(#0-*F )_XAPT
M^(<85-;2[8-_H%9'"-A3;=4@<%D;.*D8S .3&""FB$/UB(&0HI41,D\>W Q)
MV(&!L(F>VH%;*!^$5-53*,9B(LK;=>6(2N;>R"954-82I!I)&(Y&1-N6@@LH
MS*"1<4,\<$@4Z- ^,$.(\,&!M $6J%>?5BI,\$&.M,%?89,1'L2<'B./_JBQ
M'FL5<8/^+WP2-<Q#OKC2)RD&-"PK.4P$-E1KMJ@#?3##,U$K268K.-W"L6%+
M* T,7B!3*"G9NG#2VOB"&+GK.N *7HS1'CFK.;[+(MT",V##M5+#.AQ"2 F)
MON2+..@KK**)/1'3.F##PO;+LO)K/)G0'V4+W(@#UXG#/&V2 2X3PRXL-4S$
MDTA2O^#%'95KO,8#,U!@'@E,PBK&,-!1#7+")92FM=:1.CRL+1V2M,:,$/D,
M;R(KT 8M!L*4 M5"1P!M/,!!%"!F9!B=T#XMU/[HSR+/U/;F&3I&U4:MUFYM
M\C0K8RS38ZA#L2K&.]$@-2AD93#L==23#EWKMS(&P1ZL$;[^K1W];-Q>QQU5
M1A]%1L9.QMD^!L.";6/D[;KD(-S*+=<FKN**2L-8!#;(S,2PJK?TBP::S#Q<
MT3;-X=Y&C'A![MYP BL)C,&,!<\D3,$D!L^$2Z6JK22%B]C&BQ/9 0[X0L_P
MZ>C6S -I($400B,(&*L*S)F0@_W(2TZ TJQ 0^I&T,>,Q82M&,Y\S!5%3!V=
MZ#IX(K:\BPFN0^4&S. !;\"$"].\2SS@2-,DC+TH#2C%V#HEC;,2#47$'1RT
M@LETC X9&<->T?$^K\"0@SI@+O#N W@MK@ /,'< EWTRAXZ\J(W\(VL0FA 0
M@B\(0=^LG5$R 32!&1/8  )?@E/^M%4DS,,V8D&_ 1>5S8-M)48>=(CAU$+9
M0,LEY$@FZH=RK A%D(,-1.--[ W@R.I:M $V0(\5RB,]X@ 3F 85T##.N)40
M%#$L+'$CD( I?(\=<(+GX8BF#(H5FH($7UZ(@!MNJ4M\V%5",1>)8 $JY,$\
M1$*FZ0A,1$$<18&CU7 ;J$,K@-=C8H((,$,+UXLP%(E#Y <FH!N(,.6+ (C
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M1Z($)>JL%3R@6KX)&_SD:-!0Y 9!!CZ&"5K!4"K&8QH!X+#!%W# "^#@9Y@
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MFDDK\Z<K+^$0#,)2KL)0YD$V:=/^-J%!-6"A4.@34D11,XT@CK#A1(ZF\[S
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MPHW*P@T"/"AR'M2@Q:- !I#&:4H<"TZ\O"%\N_]X)1H$,+W ",AA//:!0,3
M>^)P*9'X( !MA649NM<6_K[*?<2A^\Z"@:Y8'^-W'>8!&R3XRQ5X7MS'_/CO
M^^[O_B[S:B\S_S(X?&U#'+1W=M<!&KS A+]/'.B'>/%OSN]<@2DB>-TG'J14
M?-E\=K'^%74V%R3<'%LE&  Q5LVA>EH99_\ YBQ O4;R9W;K/'[^CQKFB,E'
M1\_%#](U_?\(=H/>3\^%<"(V-]'=@G^MQW\]7<M]_85, 5<Z2QTN#]!!A0/5
M[]>5?=F9O=F1YQ:NZZ,37=IU ]IO0V/3%CEN 1JH'3>X <"$01R$@<YQ(RP
M"ZK@-V\[UMBG/3?&?3?&/=R=?=[?!AKX]N,69V 3%AK>8]N2UZOJ"JNP01FV
MS8;>0P8C&ZNLPDVI9V'7@1E\H>'+Z#U,%O_*R!<Z([O(E1GJ-7F71!]I5ETI
M@ML9/25SZ)W-5>"9P=J5 : D'(H4ON,'WMK;LS#*JB*<4VG^?4%I)QA;ET1;
M8('A"8M^H($3(MNK#.L6A,(4#IK?/RY>EWZ[-99<N;TSJ$%:Z3WKG2-T1Y5
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M*B-$39M6OMJH@06+XKXVM]K ZJC&R)(\)GVIJ4BR32U8&B^)(70(&Q5";;S
M\0)M7TE?8N)AP=1"S YR0MNT;"-.#!QL;3J>5#/O:)EYZTC"P41E71FP75OE
M*2.LHMJU;-NZ?0LWKMRY=.O:O8LWK]Z]?/OZ_0LXL.#!A O#G;<$E9I&7KAA
M4H.*BB\J=N(Q:R%26!1?PMK8R:.1,Y-;0K UK>JR8LFLF(R $H*I359.44AS
MVT>.2J/^1E2&49D'AQ..07QJ89E'LB(L#YP>FQK(I]42A(]]#8O"F)!$D6H^
MA^YHY]"A,A4_PKG5$4X40J:JEBSORTZC0W;@7/+2"#*684M,P9$M5!FU8(4%
M*#8TPH<ZI_GBDCC/\:%&*ZB),8P0H&S6&2S!C18%)\=MU(H=OS%E6(DFGHAB
MBBJNR&*++KY8(F)40,4'.>JT4=LEPD2BS#YBP%)1/(0DU@H58C3"XSR#>%$&
M4\H@J<R3%3VIY#!BB%$&+)$HR<T@6)0A3D6$M-(*(5W.TX@R%T:"S2#S\%B1
M.DQ0<R,3PO@FU3RXM6$G;UZ80HB6%:$2Q9%I/DF-%_B)&0G^C\Q$DJ@:V#C:
M2$5I"H3%I+ ,(@Z?OL33!C.'@#*E&+4THB0VA$1ARI2[,?.D.%ZP2A"/XF!Q
M)3=#FE+K,*8L00@V?+P9'Q.'B+,EC,HNRVRSSCX+;;3-QD-%4/OH>:V>VL[#
M"14D7HM0MO-@RQ"V%9&KEK;BHIOM6N:JNT^X\,8S"(#7GFLNN/C>^^ZXZ;:;
M+KK^LDNNN@2W]6Z0[MY[KKP%8^NPPO\R=*ZT%E^,<<8:;\SQ8+6L,Y<I:76L
MUCJ<4$-RRBJOS'+++K\,<\PRSTQSS3;?C'/..N_,<\\^_PQTT$(/37311A^-
M=-)*+\UTTTX_#7744D]-==567XW^==9:;\UUUUY_#7;88H]-=MEFGXUVVFJO
MS7;;AJDS#$+KQ,V-+PHR@]XMS SCRRUQ[[,.@[>(,\\P("MS6^!A4C/,N,,T
M7C@YPRCH=N667^XT-2WXLL\EL,G@ 0Z34;# !EZ(L($(.X3I"P,>>+ #-$Q$
M @T.M>PCS %MQ&.$!^)0(X('V(BC B@J<(YY\LHO[_,\3.2Q3Q1E['"L&%B0
M8XH'PS#C@1V@M(+0+13L1@(SPK0@!!P5^7* $+60X#LF-LB B3@B<$("\LSO
MSW__+K=B U"TX'VWV$<C;" 4WXEC QL@P>KVX8L%!.\@^_ "!:QU"Q%$@0I4
M( $VF(#^ QQ$ 1OW(T$!_8?"%*I06N2P@0C7L00U^&()%/&%[[BQ@>"@ B&^
MB, A&N&!M#0"!]CRA0@&,1P2U$($,I"!"-['"1$<PA<H6Z$5KXA%%,&! IS
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M(@22<2->,#*@\B2F, _6YW<9^'<,,S !0PVFL2^=8P?D]B]!,BX$TR_;,B_
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M ]P "AZ@(XFI#G!0<'# !%^IF),A!)& F' 0EDQ FOM0"VBV!$"1*1Q&"(-
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M)(0@#I15!O'0"L/PH+70'C+\]K"0!\4Y\5J_?P6D#GZ>!W1FIR$<)+25![4
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M42%ZH%@'-P#4,75(:!]JJ,4\C,(2I( B'K=XX'K$P190S*,-L @D=>(QJH;
M0@W[  4?YG$(3N3!"ZV CT#4N ].\&$?B5H/-;QP,[&)(8#^IR*<J4SF'BW9
M84KJV5AO2(.=/*R#.6(0ACC$T CEB:$5K8B''2(Q"&J@3(S#)&8QC7E,9!X&
M%5C85B1PT(9(4,,&93 C)FZ!1Z)0X2)JL ,GA" .-(H##GDXD4,@U(A&F$HD
MA, 2O>98KHX\!"VWT!,<VE!);DS3#M#<1T?^! <&.005.^"$&PN"!5.<$A1+
M:0-.5D3-2-Q"!CQA(OD ! <O>,$.>6"&BCH"BS80(E_))&E)37I2E&X.%'"(
M CBSQ QL+(&,Z[!FV"BT35BH(PK<((\Z(E>& 34$0D\#2R1,@4XOX HL_?0(
M><"$"F%@"&-&(".']@&F2V B"@[^C<].!X(Z.\ ")>ZYA!@X$95(8(()W B@
M+X8!TH[],4=YX(2QF),;!ZX#%;=*:5_]^E? !K8PL. &)]J2I88MH1:&,T7B
MLKG-6\P#"\RX9SQ2)0X[E(B19L.$':BA!FQ$"PX1 <L\&L$$<?A"#-B @S(:
MVP8Q8.PWJF6M:]<1"3O8SHZG$T,M3'$(U2ZP%<. !A4 M]E(D--8OA"&%Z"!
MB51=8AAP: 4W:B&&81RB%E%HA1=JP8SE"%:\XR5O>9,YLGDD=TYP&$8>U$ L
M9>"G4)R BBE$Q(EAW%-Y@SC$)7 3W]L1PF+S$!<U!D$K$:DC#V70TDB*$U]H
M,.EVF,C^3'H/\>!YJ&,0AYL')J#BBT%<PG4"'L;X3''6AL17'7>ZIQK<&@D^
MO*TGU'B9:3<$AP'=8A"$N)AY??QC( =9R$/N43PXX1,D)SD2017')92<9$Y\
MKA5/3O(JC4QEGS2"R4[&<I0[-F4L1V*5ZSARF+<<9B]O*<QB)E^9L<SD-7/"
M;*UH!)>?;&4W/UG+#6DRFJ6\9CR'><\"L?.3Y=P0.A>ZRFU>\YF[;#94 )K1
M9N9SG.<L:6[E^<F.IG*:P8SE0(>Y7'U^-*(Q?65*IP4BI59SF"<$C35W)CZ:
M3O*@2=UI2&,:UF&^A-U\(>B@TF;-@(LTEAL1:D5'HM<-\<7^JI6MY$/?VB>%
M/MR/N.$!  P@VP/@=K8!4 9F'V#;W>ZV!XX2CQV,F]O:UO8.MH-M=JO[V^%6
M][H!8.Z.I=O>Y : NP6"[6V/&P#S3HNX]UWNH\PCW=Y>=[?]?6V&LUO; %AD
MP<DM\7LG?.$''_C#X2UO;5?<%P:7.,+CH^^&QQL'[PYXPP<N\@-</.#X5OC
M.=YOEE_<WN"V>,2]C6]TV[SD[<YYRR<.<YF;O.8"[S;._VWT@/-\Y$8W>=!3
M'F^/0[W;4H\YU3-^<J&7W.D03[JV>5Z&B/,;Z!L?.@ 8(I*TD_L  R*[SE\>
M;ITKG>TR]_<EZFWON3<$[7F_N\7^#]YMA@3][T1_>ML'L("@HEWK7_?% H0N
M<+<+B<"^X'SG/=\EF'E>]"9+,>>=)OJ&%4I J.]\E["&^M.37G&LY[QX-D][
MKD4,][)G!NYO ;B5X3[WKZ<][X4/_-73'O3"EWWA),9ZVR>?]:X7QNY-TWO<
M(U_XKF?^]7VO?=QS'_= :PCV:0]^Y=^N^Z5_/NJC+WR<A+[XWJ?][U6__;NM
M?Q_FA[W=4BM\7 F^\/L(_>,_U .<U#J]T^L\83 ;:L _;JD^W!,<V.L\]&,]
M!QP_TB,^VC,?(OM $ Q!$1Q!$BQ!$SQ!%.212),96&N$5E &B-"R>("%X3$%
M3 BF 1'^F:@0!IGA!BVY!6BX!%  )6:#B-$Y"TZ@!B=SP8Q9A]\[B[*)K%H2
M*'2Z!&A "1]LMBG!AC A0B,+$]0!!3T"IT:HFE6#!EC#A+YI!1%;A]3P!?-9
M!S94!Y'9(W5(#>P0E]P8J13L0S_\0S&*ASQH!"JHA4N(@N1@AD.0@0(2!A50
M$4XXA$:B))&XCHYA@MBZA6]R#SO@ R\@HD/(@QMQC214%#78)=GQ DS@@T/
M F6P@=@HEWEHA3+8@2/2CHZXA1; !/EH!%9T"&X8K1>*$CLX(E^B E^4@4-
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MA"B[-J*1 <TZ#&6XA9M!F8G!%8(A&&Y1AG5@!F'PJ8L@R, I/RVF!J&1O88
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M)@$CV,6*Y0U@S66ZANNN=MGBH-S^HTAITFT#D*W6 ]@ %K9$&$XM%6#3M&
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M(X&"[I@(RP4)'Q3=+0B!$("6T&U &8@#$]"9F@S", H8)U# !C#D0C;D0VZ
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MR##,)JO=I%^L R? &AT9T#"0$2S< A8, R&  A90@Q>425*V11Y45CIJD#+
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MPT#+T R"P63/#*GS?/J".Q^S/N?)'O$!*H .Q>[#[V1+RY18904K.X>&+QP
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MO\Q3@RII__9S?_=[__>#?_B+__B3?_F;__FC?_A'.2E.?WQE/O]@^?7+?!D
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M$DRR[=\4XB $)PX!OO$=$(&@.UYX/#<5;$1!#2TPA1>P40931($)2[C%.J@
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MF4%=J2$/6O*"A$$,-S(E='%54T(<1* W8&$)\H )\H!69V(=[%.%\L &Y'5
MX2 ]UU-?UM4.<, 4;- E^I5^JI5L!Z$5QM0.[* ,#+1 A4!4!S5K?O"5#.\[
MUX%E9"/@>"T>?,Q1J$')F&%&Q0'E]! 54L1V.X5OFR1E$@DEU@&D^@\OE*$^
M2$5%7>7^$HYO.=8A3%+$>+>&4<FJ%:Z$''@+6HIKTHH+&N*!4:$E'IA!VS#A
MKUAM&*IC%>-E>UW-%&:T9\CA7H8A47H45?"E%70O9X2,$]1!=VM$][87LK[)
M0I0!W'#M*,H%638$V(B#@;E'&$*12RCF?HQB$/C 1:N$"3IJ'W00&QK!HSJX
M=F\7%0H+=UL!*#9(,X)W54V*4$JLRF9"6=)#1UKA$(S@%CBV%92A%<S7>)G!
M.:A,;'J72^+7%-@1%5;M#OG'#WU!32:%!#6#057$06EG'NR ,LE&&/+15KC(
M_=*H;TF#$Z*@#+ L<C:/6Q&(D<S&]U8"'8-OC$E#'9BO-)3^*>7F6(]/3XWS
M>(__^'!$#^RN&) +&6U0S^P(V9 769BJ6.M(CY$CF5_6CI(469(O>9+[^.4@
M&9,7.:I:(Z"<(MM >8J%XI,;(:!J55M1+O)J@FY[,";@: 9)93"U[=(>!DW0
MD=RRYON"(F9,E-_:@Y-;@OK@6.7NS?Z>)#1>C!-X#2:(K3A86"5\@1KF@6>2
MXMVVZ:JP0;/BN"ELF095V25V>9S%65O#V2:@^26"#1&OJIBK IRIS9SC <0X
MP^%HHM.<&6#480E&$0>$P CXP)Q?0AV88!1M *!3<"GXV9\3>J"I^"X0C";X
M(!+$0)];0J76))Y<!:YZE!G2@QO^#J&:K\T_#(E[R.K',H,;#$:0-$,=;FJ0
MJ,I55V(=?NQ<8*U'NVF<S&D=5J:G-8.<RC=[I,<W,"$]F,:<R"E#.&.PP&<=
M(D,9B 0T4(V>I(DSD#%KL@<3KD\E!M'@1+*C4(+>TLEKYN'X(L29A*Q3$LTW
M*$T>(\0_>$\EN">; JF-C3D]XL&D,89KIBE4\MJO#8EZ4*VES1HZ:KJ:04.:
M"NE#CH\S5GIK#KL16'IER &<IFF<RDLO?AH^:F08/B2^Z,F@@F]L;H2T-2,X
M 'AKZ(FLM/KZX,6]@@.I7TI?\,7AKL<SY#IK.$$7VWB0YF].RF-5;(P$>ADI
MRJ-[;$S^!(Q;*(2[K(>AN'FBYN3.)IBF#)B[NNHT-CIJ'B[A$-H"H8!B&-I
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MF,\M&-.[W+>OO IAC3H.P8>,9!T:W@.%63>B(:-HIQ&T\B=0NT)UW?@&:-3
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M"!I4#D(& EXVS_ JS_/X</(X+^ODK@\W+Q S[^SN+A %<>H$+Q'ST! 9+^P
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83?(D43(E57(E6;(E7?(E83(F?2,@   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g93142bgi002.gif
<DESCRIPTION>G93142BGI002.GIF
<TEXT>
begin 644 g93142bgi002.gif
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M00;A(T+8!M"WWET/!WF300F&9H(<B&  0H!!"4Z7 P  ;VC BP$ P.<#!!P
M@H.3'Q%^-X0%? UF"R" "$1P@ *P[7?U>R#N9! #VF6P>P (@/$0$#TAG, $
M.A.@]M('M^3)[P1"B($)..C!WI4 BD0H@.=\H#O>^8Y_/EC>V@J(.[;YL @'
M8. 08) #,,IO?L=3WM#^I'BZZ54/>P 8  ]X0   C&!GP%LC[D80 "CVT >Q
M2]X:<? _1 [N*:SS@0$$$  #'   ^(,: /JHM+\!  !*8T 0/PF !(Q   P(
M@.0F*0 /.N"3#=B9#T00@ 'D#0#&NR0 $#"# 7SR!-23Y"<1D+9/$F!S, B
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M @K@.C.@ "T6!=<I!?@YH8XC/\,9!>(72P04. S@?G2C-'%6!BZSGT; H$.
MGTV  \2D!MTY!!B@ T<!H[2E  Y0 'DS PQ6H4-@ A<F-?@I CQE8EU)BWES
M= 8 10H0FGSY  =@ '\T B"P "<T/@7@  H@.@DP.#/@.%-Z C+ 4T^S 'G3
M ,1#7<U3.B2( R5@-R=0 C7D.0OX- K04Z?3 *=%E^@V/FH:D0YP3,E$  BZ
M:S"0223@ %RJ,R!I %:7-\[I U:*I0>&:FE#@@R@-"/ 4UFZI7Q%6Y842R&
M  XPB(YS/'*# ))Z6D_^(Z0, *CZI: 6-W<'IJHYT  @0  C( ):)$N". )K
MLZ&]4Z-0!C0$$)XYP !7FC>I&DM36JKB64,3M$4/T#[0BC=5(XA0U*WABFL
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M.L"Q/L#,Y3S $&O00H !*YP2GNS"&YK*QFJ>G2H$$/5'7_JCV-,S#+ [2<,
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M SLP 1S0 18 SNJ,OAJ0 A3P AA0 Q[PKCZ0 A"PPA2PZ"Q  2K LO/L 3;
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MWWSIHV^#_/:O#S_[\/EPOGU(XN?##^[S?[]^Z,.?][@W/_>1;WX#-*#V]I?
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MCD7HYWPI:Q( @#B>?P3  AB@@.QV%Q5E5>$YD<R*W@KAIUF3P8V%4((%"&\
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MP.937^6=E*GI   W (['E=)P28*I 9SPHT)#IUU^[0 TKEP86$W##M7M6@]
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MA9.* .9KC?.L960" 4SN)2XU7G6J !R@ZJJJ5.<K 4S H9(@QT9  7KG !8
MD>ZKL 2@&+>TO[XB"1;O-1E@BD]+"?JL8\6"8QG9 60GC,_XK/S7A$T9%]C^
M3*\RTQO+B9X4( &XT[A\JY6G= !VJ0"4JX/J2$US$]30#)N:BT 1V6=Q,[^8
M*@D< /?.*Z*D+>^LX+W$<@18U]L"- !.BV;UM/9^1Y6MMWZOT56_&1;XR9\4
MK:AJB8<#R@3T:I=J:#YX*@"*J50'D4GOS4MW\R5@MFKOJ2O<"#;SRQ/AR:JZ
MS3])]?(PF01.2  .@!K;N/D.8)*ND_?(N0A74C+-UJ)50?KN2)98^*/ M(.
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M@P(,]#*"" $8@$.&'W$XR8=LB,5 #$^J)80,!9Q% CDS)*" 020L\$@I9O&
M0 /.?.+> ? =X=A:) 3BC$>@L#/$(5>(,,"->.AHS2_>(% :>TE 1@1\H1U
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MH)(Q=)HN)@&F/-:K39,HH0+6\0T\N(2#<R-""/2!,9;94(]\1 Y[G,@7$@1
M2C'@H0]11TE.'C AX!D8 QLH!(0-4X)V-,$)].(#&8#+) C@ 0=_Z1(>\&8
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M64#1Q6$L&2[$JPB$P @8@+T:01\*0B2DTP@,"C3V!2@I%=?0JE_9EY(\0$1
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M<IR 'J=?$^+3$E@'5I25Y #$#$1#_?"&4+#$%%34<L!>8DK1(==/"6B$KLK
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M4935/(AT0P28.>I+>#  !H! H=L3R0"F5;(9<*7^NORHC-0(T  C4$4 P#E
M.)L0". \; 8$<$ (!B ( US$ )N %7AS(]#0@,PXWR%<# 10*P5T(W&EY</C
MY&, MHG!-,NQK5"66S@S/4L!!#,>?\5Z$ /4J@!^RZ!L4$3#MRU M<F"56L)
M4S4.&B"( Q"#T]:;,^:$ P3\$+"R%,*'O'94- ]@+T ,8(7E7;$>:JI:VRAX
M / :8!M9N_ G"C!C!X G!Z7MDH91YT%=585EL$2R"'BS,6 :H+W!E0$."  "
M!M!/.@YXS('!$XZ_8F:Y*SX']$@PA ;4V9U /=@Y= -!'/RQ /RPKF7$ ,',
MT2'#:=[+ A:5!N@^0*'^TQ)!<'G@22J<8,I!Q :2'5  MM4Y'W\LG&AMTMG:
MF5HVH%6U34Q@)Q-,81;ZX(%MSX$#&%@,*:_!08$>RH00."!=3# !Q6:='EBG
M>A;2B $Y9& 86IV@U)^89[ !>! SP> !(=!.KMV@[1 DH5P'J15ZI!4ZF;Q:
M!%.(-2Y <!L_S-0!JI3"".3"#7I_PBD&&:,/ZJIO;D,B3,R;P@QJ116_U6,*
M,GC ND52+HHMJ*_#-IF_S<N(&4,RPB\*@:^U8)!7:XH;?0VL0:BBH7F?O-V,
MZ"NS_PH[I"3LWS+1]E'X*=4I1.5%!8<!KD/UA7ZC'#TSGSDP^SJ":D&$. '^
M_Z>PM2"-&T'"WD._.#=$,&/01#;<7,1A(T! E30TTDY18%I=L\"#8)_CWVA_
MP,:++H4\]!M7)+B8Q?']4'*( 2DBN)BLQ\YR1KIAV2>0&PY+C0-E%OP!7X=!
MPJWN@'.,J-4SZ>SDWY #7(;6\K$#%R8V_WG0AU[T-<'LZ$U_>M2G7O6K-S5-
M0]\IVGT>=Z=/-=RD;@"ZP:XFM5]0+'D_B(IQ*OAO^+T):X^XW>NN^+7C_>\+
M#LO>0\+YMOQ4\4W8$^O[)/O8MWVEXC9\ZDM_**DF_Z7,#_[PBQ_X-*EQ^J50
M?O8G/P;;WVSE9<]JUN=?__OG?__]_W\ #$ !',#^!<F4ZVNU3M$\ *0_ FQ
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MFM>W'=>Y1=/1;(<",!C3:B1"$2LG J/+-1ELN#,#$( "04DZZ"XBJ+7%80?
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MU\Z!4.;N-W  ^@(#!#$(!EB3\CV'!X >TE@OT#2D04YF']A31]P'Y&8"J3@
M E@7DW#G==%L29)0J I1(]H5<6W/Z_28U329U1P"U7S1=4@HI&#P,*EO?S/,
MVNRD,:+M A #+BSN6PR-&8KO)VV7 E@JV@;E0:A%5/1NP,#P.)T#6KH, V@
M3^"MBQOBSS2B+[ Y@&+-,D^%;ZO-=FD#-LLT.!0)-5:&P*-+_9!LRWZ]GS#*
M;OC9&!P$D_P^@A(IFL3*BGQ!T'C+EE3!:=!!X$-T$'3'%ZQ*W>#5NP&--+U!
M>!3(/P.ZN$$<?!09@.S^O:'<\\=-1VBD271( H?DK*S\"="8@4=L=5((=&@T
M/CU/0R5!/N0[B%7IB*/Y2O5[RI^0R58_B!@<KAS(15=E2D04R4\?RGDLPJ,!
M08O!]&?7\WLDA=HQ2>D[&FX_0F@WRA;<=4>GR.O+=$8P=BA$]+=8]2ALP1R8
MRB00=A&,#1Y(@JBS<YW0][NT0 Y4M>V[M*J;;W^G0%270-.+TG="R8(?P YL
M0M 3 >BSO*<%/2UL>(S?E"!>HD+,>(^O0*9)GX\?^?Y[>-T!"K3=O-DS>9)O
M>9=_^8)G^5J2>9BO>9J8;%738)O?>:CE>9__>:"G>)C'>5/3>=!##N$F^-W^
MR\4.I*3(A)Y%;@.:U_A8'+^9$ %]^.E/Q$RWP<]Z-1G\! '=P)5E^$3^I F^
M>U)P(#%+,9WR.IN&PT&B^)U&C \W$ Q20)"U6!I008-OFY54&P&IIPG!WQ2T
MZPF_C[Z"&T.3B5/:X1DADKX(!TTF0"BX\9CBVX4*';E-27N9Z)+K9'CQDP50
M02?Z:BAI3' W@AZ0\_H#EX8X:%,FV ()-<9/(2$ZMU. S[S12TYQA/6>P%Y+
M>9D[F\F>;[7Z+?VL $XF^)>9B &<P@YL*.M+" $ T!?I$NM'E EA7I;DKY2]
MV4V"FGJ92"II-(@HTX>^JN1-.>#O9W_QB^.A$/[^F1!F2/A^$QAK3?4G #$8
ML]T5( @5? R3[XCTX1#)YA&$P.%,!!F/Z<PFHUF3@F=E++1)$,C'(Y-S@?&Q
M,#R6#HET,I3PP0K@0G@\DP 0<[3@X$-BX*-P5H*E!ND#$H(6:0F9(P P4GGI
MZ90)H/A)ZL259')P8 #C<X)P<,@0D">C<, PXU.2<&#R $)WXG0RED9"XM,
M4L!PDE"0#*-@P("C]7QPAK-LL""354QTK8SC$$)GY.-P@*".I-#00,G#4 +2
MVJ4^LT!RZ",CCX,$(1@<46 %#+DF(@RHXB$"P %P/F80$# "AH$&!QI<BW$K
M5Y,1[9(=" "B 0!G9WC^/&BG2X0J$4=(S&SR2INK  6&I0%!$X>":4<:_/(1
M@A(#9LZ@)>/!#D&)7;V\Z$HCKB%,28U@/;!S),09$[T>')G!40% 6 :2+:#E
M V0U73(6&("BZTB.6P;,'A#0($F#J3RD?#OB@!,25DA(A!A X 0.56U]O/U"
M\@#-) LV[SKA $">!@D0\,B\6:9FI $F.C'AIN(!5[U I#$!"X2,BS1'($"0
M3!FZ!,.<!$+H [>Q1;"G)DE T0$)&,YG,"F 9UB..D?LJ2V:CZ&!W[KFI4,3
MC $#2J7:\]"DN#VI4*/DESHPXH0)$ZV<)3==@"X.E#!9#E>T,L(80N3@0P'^
M#?3!("K+3>)# )PP,, ,,A2 0P((QI;$;H0D< 9&N\SVVA@'D(- #AOU(<DA
M2U!TQ#5FZ"&  S*QYP0/:8@EPAD5Y7&-.#-HTXMS3>!P& @&,8:$ X?  , P
MP/APP(=)E&  #B[NET<,L\'FPP,*'E#"=PJ<$,,HR!TAXB*')!#<$;CMP@1R
M!N3 1%(5<K) AALB):-I(A3 ('[ZP?" 04V.,0D/*ZXCY!,A\$  (0H<PHAE
M"X1 TPQ#R'" @0@@:% !)9PF %@C',*# 3*0U00"#]Q"R2DWVD$"  @TD(\"
MR3S B:@ *9+F04;80:4W)J0AYC4%-*+F"2>H:83^ 800DR5_FN%0!0^=!JB,
M"2 <PJ44!DSE((3&*2 6$2)\AX,B"=::UZYA!7;- D8L48EW=B!07!+\@.-D
M@P[P$,,0MX)!@&?V7?+>)A-_0M_%I- AA@)F[>* 0U@F,((NUKG2%JA#Q.O#
M*:<@0>9/N5IZ4"(CJ+P0$N?"&046 *?8,HL="HW )"0@0$\99^1 #@\)1)@%
MJ4@)^7-R8^ PP# RO)P$#R0T0(!!!^3UQ%ANF-" #"DW=$T:_=34 $@5,4'F
MI$HLP, ((C#PX  ,D !6C'#.YF_7BJRW" DQ,,$$A5A0&+2M(?A&P@A"<HQW
M-6B, +9!Q![M6#!'_#3^ N<\5PT.HP@04-AL)QAPLTPD?!=TB" H(( ,,"SW
MQN73Y%LIG/,&P$3A>CRP>NN6Y;TWB #-3@ !2J"(@"[JB;"WE R(,((8M3L!
M@]]X1RQ"8 #-1D?)7"5>DUHNYWR6 FA;]LP1IEL7N*Y);TUVX2<7 @.9!$D
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M;I:0@%!^,,!6<4%EK&YQ@#&4AFPET"917NH OTD6"4N@+A.>^%*--&  4S&
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M R(W T)WJ6F0;\VD"Y3*("?0<[J@-TD@JJ^7'';P(R#0EF0S F]Y%L! =_@
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MC$7H800PBK$N#5C;(D]3B(/X0@C*P(P :$>$:+A&DCP14!Z5DH.FZ*@6G#
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MYC+32--E7;FV=BR- W/ %R@^7G5=[K 9+Q:!/  H !JR 94ZC=8OI5@K@@]
MAFXJ8]]:. $!>!( T4A5WW$0#'U>%A0 F"42,S#'N9%2 %IVQ>'(X9F5:S*#
M?YJ[  <8+A5Q\)@$U(D[-;G)-R^"\EP;H@$+D,$ZDQ)OCN*XW%]%3U=Z50KW
MX*0KKM6G$0?P1A'5Y37^70G %0,#AR)\I0E&F %*FC,'>\A@ 8]0Y(XYJDTD
M;\%$KZM+951>BL\XP97V "+&T3+TKM"3BD38L!'H@A09C)L2].Z*W+RE9Y['
MIIC,YI9^WW8?E&Q=7$XE @P*T1R/1*.T:D&P1<Q#".TH0N, J P2#A"C1E38
M\D9H1,4G]NF2ZZ$$-1J0(TK A*)X9!8LR@K&*=9+TCY.Z#BYPDST;049]GM]
M'S5!7]8=GU><T5<#CT*,!$#X(O2R"(T0MR))SYUFQ:/T9Q*J;31N&XQ'XOF[
M*3E03A$ );Q)%(G'V P4L0#NE#8;UF+"'[+!@-(CBR6&2.H#&$ =$IQX ;W^
M *@10"$-!"! :&30,*C8L$!VDN\;AB &BB*N!B OM" :K*5)<&+_7JT*G(XJ
M"L THHX!#; 8&.  5&, -B_KXD,"E6X8HD'^2N  U($3Y.],KH43."^F.B%X
M4F+69+#TJB2YCJS^#L 'KP\ ?:H3 @(BB&W/"&@!A<!2'B=<".J'EHVGM,4>
M"H @9% KTD"/H,@/J,, BJ(1TN(B[(&>9BT:R$<@;N*MR, <D@-?<FN[ $$.
MK.RV&-#M(FT)R,#*!JW%BBT7X@@'3(.>P&$I^D*#/J/Q"J'RV(^WC$*DGFH(
M,JP.+P8+_@ 'F."K#( FXH$@WDXQ%B '>$ (FH/^$YJEX;*AB\BP#H.C 9 @
M"T\OU X, 11@ 180%4WKLG217NA!%4+ 'D(@'JH./;3#D)C*$HD!7G8N^( B
MCM:J#"P!&CK#QXA "+3C$'$@$7W@,V#@KZQQ&!8  09 .PP@ 2@*I#*"%+GN
M".H$XQJQ%VGFL1+ $[U0 )QB!6&O'0^,3H@AN12#%;-BYS[#=>2 ([CP&:?1
M7 IJ;A*.7%I)[K@0BKQMZ=*C**@B$E2#*K)!-?#)B>AC$<8(#<9H.E*B$$[@
MK=#@K8CIK69 KG3!Y%@C"PJ!%7(@G7C"P(AA.2:AC(P)$;NBM/R(/12.F'K)
MD++!"AP)C?RBRGH#+*C^(.+^(+>X0PDBDB?"Q0Q((2#FJEE0TB=Y@HY 2BOQ
MP94NAXI&$I<RPQX,,G(0<.&V(HY>[C3FP,H.#BXU48VVD2ZSH2=M+ ^'X2M>
M(@G;$2>OPIYH,>R&"94V0A$$A"*1XDAF#>4L3YZ:KKRZCMUZ[@\BX4*4*A?T
MKA(**:#J;7"H,/!@@G!0TSY.@ %<4QA& )2P; $:H%?F3@&FHR >J %LJEE"
M[D)BH.4.8>D6P#49P)9 H#AI<SV2TS@5H!D28'(8P!-20@88H#C-(XY@@+LV
M8ORX<QA&8 &(0*T:CP="0 $80(/@+@2JKM!$I.72\RS.,S[;@0'683Q*@03^
ME),^PY,14"M!%(! BM,U%:!93J#J0D P9D !\.0[#W0!$O314 L&$D! 'K0V
M68(!HF[$3B '%, \#"M*7'- '^%'&$ U3" 9U.HXBX((0B 9FK,XWR!&&> Y
MTR Q>.0$OI,$?,(!-BH\RZ=$;/1B%I2.8G,=3" !0@1SJLX\1*!$32L!WB V
MO6%!&X]"Y8T!H*(YK[.TX+-&'\CI]I,!BF)%1Q1*3=0^&Z5$,/0L3E2&:-,X
M7<X!1G0X,[0M6Q-"UV$[M4\!\*YV=M0G'B 9]%-.&R^(J- T'Q)P&)4=SG$8
M,FV_WJ51*952&;12,55;5C-3ERU,FXUNT$5C*&;^8W9&:$IU:K F56<FGH[F
MB<(H:_9#94A&9E0";6YI8FA5(VRU5'$U9)*&:]Z&9!SE8W(U;7256.TC;)[&
M6$_U6!T&5ZG&5&.U;<X%\!!U4:N5;*9E4[EF*7(A!^!+:J254Z$&8(((5K'%
M:+@UJ/*K8K:%5+N57$,571KR4[%57ID57_5U7_E54OOU7Z.%6P$V(NJ56YQM
M7)#*#=H@IN@(J1P6%_2B#=9A!A@"!F# #?!+AB0VOH0AK5CB8LL$&Q36?G#
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MQ4\Y.4&+18&&4J+&&)TZE.".!D#&&+T2=@.FT5/^ >A\F'GC %Q3J3@!U!>
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M4JD\(C(&&"&C,QE@0!@/9%:L3+#U@<*& (#D8P!\)$##1RCX\+BU"0" #-A
M 1E. \ A@0 ##$# (<!"E99A0<!)R2 /7$'!(M)5I<_E&,% XN(8 $@56U@F
M0(D/)%>@5-41W9'/(5(.Y>_2F,!#%5V.#]C!7'&J A*HP S2T%BFB / LI;S
MS"<!@$%.0 "J0*W1LZ&:##?4$BB =!3J@(&OZ1K/44ZH2>7ZE'JP!A:I+ >]
M@!' J P5<Y((P'EB,!^<$E>D(<GW;!D8 \] C7O^-<J4FDG2P'#91^6>2GFK
MO)$;24::08>"3HS"DF0>  $Q]/#QP2G/@GEJ8,P08(*=G@%4$@20]R1$)'E[
M0DES">LKV+!@>:AI*?8LVJ]D:Z9MZW8!*&HA1&QE,B=N@0'(9"@P%***C %/
M?2C@R'=/"%^%D900\'=7B#$*S!B%&%:(R<"#30R8,2/N'@)#1QDP"<(I8P,#
M$$P!P2>'@2<**A4(@6/ N@4$/!M@E'=&Y+@#I,% ,*8!#L!X!9PX ?$P@<FD
M,^/]'?Q0XJ\D#! X,&4&@=P$*%<!H2\)1\P^X I'YLO\^P$GZ KG6"* R?7+
MYQ;P%4(P,PI(9L8!> W^($<5D3'!A6L^F% 7<D9M=<A 2&@&"PX.')><>C[D
M@  "R>U2FH4 .MC99]R11!X/"("&H%&'L';B.FR(!!\2(3A!'W9>!3A&=A>"
M50)H$7*&@VO^#0##=7EQM!T!,Y+F'A(@2&8-81SI9\9U<L@0@ A4@/?*$27L
MYIP9.1S@S(,D-;",6W&*E4-9<MH)"YULW;DGGWWRZ:.?@0HZ**&%&GHHHHDJ
MNBBCC3HJ* ,U/DIHGEP\ZHF>D^XB%J!6V-GI99>ZY0N@H(9ZZDEHE?IIJE A
MI*FJF][9J:EGT0KKK''6*N<^N_+ZJEJ>XNI#(L .:V>EKBZ:ITC'.OLLM-'^
M2CLMM=5:>RVVU:YEJ:/,XGJ$CUZ!:ZM:IKHTKK'!RCKIK:T*NZZGNXH++[RK
MADNOKV.]NZJRKY[K+JJRDNIJO@BA>Y(_MH(Z<*H+ WOPI@E#/(JY_+9UK\#T
MII5PL YS&C#& #.:[*/F9)JMR"BK/&W!N:[\,LS?KMQRS!?72?.>WFH*P@(,
M,+" 220LL ",0ON\0)A?G=#SS^OP?'2-,SBP0 .4P<#T C5F2/5H1HPP-(PS
M_-RU \B(A4,("C@@8EA$\Z# .C H@*45#0S-0 ,*,&DV#PPPV'//<)=0R=5'
M.P"6V$>'L,P,>GL--A5;-S#:TTU7R30#@BN =^;^(<B-Y0D_9^?# X<;X;=8
ME6=> @D,^%*Z'9@#_54(@#-@S==')XW$T@N,[D >#B8P PX*Q!"#[50?$;KO
M<&XJ=P-8\M" SS\_,?W1F4^QBP-POU0$$@^\8G?U>H=@^AP(2DTU9=@??7VD
M.&#-P/C5:R\"YN15,<+FU"]@-@EF Z,JF& !;#L?$DP@NB/, ',_@T?V%L"3
M*C1N"C!(  YP4#VD6>%I$VQ<W.8&EAC8;6VV6 "61N Z) AM 9;Z' M76+(Z
MS?!DC1J"(&JBA!PJ@!<Y% 29JB""']+"!SC,82UBH(8<RF&(/ZP%#)8HB-S\
M,'AWP,(10'$6!.10 /K^VP4>9B"(H42A:Z. PP])<  "!&,81Q2$ ^(1A1^6
MH@J0^"$"^,&%'0JB"%%\HA&)6(LW B".1$3 '89BD!P68!E#.-P5B@ H0AK2
M%\"@PP^;584W\D$1/S0)-QB9G"B 0(QY!$,)./'#JF EA\X 2RB3AJDN6@.-
M.0R32^ZHR5X@80\^L*4@U,A&#V'ACTCT$#"]V(?HY1 .!YAE#D? Q1]^\1F9
M),P/M<0.2"1-&)58I"#ZHP4B.H>(W$+"+;HP"#!\DEAO1,8XGU#&3:E2$ *P
M P!&PTL^ B !\AA-4G#&)Y(Y:BV:?)06J8 5,K7A%;PD2U'VET]F8,&7%"W^
M D6>,(,A\""1%]5# )X@@R$DART..$\"!* $2T;T*V X'"=VAY!"BK$>\JBF
M#W&0Q:)$\A<M?08^1\-%KV@A:=Q@2ASZT"P'/+, 3C!% /R94#!@]*='X*8Z
M9P ) QK%I@>(1$G!!Y9E#'$*O/3I,TR54(-(#0#@<H@/3D")9=R!(PH0 %7,
MH 43<.*+F<#=>, R@ ,8H%D][:H<?)(Z(DPTK=-XS7JZ\=B>8#2D/M@H ,+*
MF*1B\0@."( 9%#M96]CT55CUP4+]T8;'5*$ S;J##+::G#M48AE:](=HOZ(%
M2WE!C"V!JQ+DD(.DP("=]AC$5^CP!.? @!/ZK,/^$$%P!"7@P*..K>$Y1Y82
M6#FU!",0P4:E0@4Q/&,$)!AB'5_B"A-P(P].)4$)##(",>9'KJET17P!\ #Z
M4D&N7!A" 4 P06]"8AW N P,9JN+<-&T'J"U[J;.^M[O5E0=Y@V3(N0! N\:
MPJ4'^8,#?!O( /-$"_DAWB\$ %^#_*6[YAT!G%BBS@P!@&X)J,,A"E"$W'XE
M"I2A@PC,"U<ZC.#"U7QO";BXB@L/@PYT6RFQ:*B%^V[XNT](R@ <8 ) <7.(
M9KC" 5A'W#Z$N<@#I (HQ&@Z"0_SNA,>8HA=085 )#;,@]/%,([0AJ& V;OF
M_46;;PPH&?]"O!UI,Q7^VD @J="!;8(>;9_-[!5"]Y8()1BB,_HII@8KX,&Z
M@,40!9"U43:6#H6V@AFB\  2J-&M[%*#3!EE4%B]L01K/,DE,UG-.0KB ,EY
MHS]WNTT \/6'SY3Q$83- P<,  XBB<)3 L 1BYZ%MISR0QP24  ?!^NLA"P"
M(66085Z'83 G$38QD=,/9L,! >C>![!_3<0IH-L+W!B7J5T;"!,$H!*@FJ<U
M<R@23$;B()MLID-U'5E\N_HV $C:E.L)!_#110VJ^(HB/ . O^! B@'( S2#
MXCP+%=('MW8S'XX0T&L0,<YF@80<@ ERG\C5)"9K)J#9L?+G'>2VH[4C 'C^
MXHB%LX/-9_RA $:NQZRR,YRAE:01L$V"!!B VU\ATA)CT%<D) 6MKB*WR%]M
M\$;I;%*'D$$,8,"# P0 3AT?^""LO:DHD( 0:%;%:OF!OCL4N^XR.,)+J7"'
M$@#G'U@I(% &8-N?:B>I<Y(Z6;YJQBKL_.RQ'<88<""#+P 5VC (P'E@@>Z7
MBI$$:/M'&PP2O/4<+B](VO@T"*!YSBN$MYD]*A6XF',%A"*]8 &X<@E!WJ1L
M_@M*U\-XF(($.FA]&#Y0Q/;8O@QNI((FQ3:!YF60 [19@P><0-\H!@"4/%X!
M@TIXBC 4D -"T(T*U'>J+I3Q<S83 A+JWCMG,9C^%)YX$ZJLW<CZ;1Y1Y%X
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MGJ$54?4#::EE9TX*00$O;4[*5O?70J"SF0W9%K#:CI*#"81"&EX4ZTC@(LJ
MYAF!K8$6YO&! 30T;>"&@?( YWD?VUEC7/GD/F":;M28+8 $5FB)#PE!"#22
M:T$" 3# 5SW%$9356'C@I4U!=RD!%YA8+*Z!!Y[7:+A8D5T4"4 C!F>7#\![
MCZ&F$6QT%/"$GM58AAG N0/$ =P!"+BGZYY!F D-GI79G[T7"2S.'3!\+)!Z
MI RQ-6A!I!09??+FKJ]:JVE8G*:A3,KC ]S."0> GW$!5;'."*2M3S1W$:C^
M%"U PE.0P!Y\6K+)&2_7F0F ]%>$@ZC=V"OL\Y<H00]C(%B\EXV6WZ;YT55Q
MPV-4GCKDYT+:&(ZQ4;3W6XKE_"U+9V%PJ!0$0)D-)S"D_9!SHAW6%[&5,U9@
MN-@1O*(,;*.$0A*Q8@IELM&=53**$84V)>F@= [P0%(T*.Q1= !4%5M6U$]A
MQ6. ?6EQ0G9Q46'\(4A]&33"@JDM  (,X@&T00(4QI0W(31O8E$T@FT5D0%K
MED6+'B#@ 3]L,<< '"PPOC6T@>L$Q5!PPAW7@>JSOD)>AD]P0F*)U<\1"_*S
M)1_(F%P=3O^&Q2(^5U ]WIL8P '8!BT4".\3_&'^13=!F+"%!\!S31[AHT1F
MV3?C7]TVSP9<"=L.30&A?040% H^(G$! /EP!@",!RCD?#( @\@ \(C"(O$$
M,.!\(,#"Q_U6?01#=PHHP0P&6*D9L';1 $"CR'7;@O.)$<@B 8CQ"0$@\=$*
MC)2<#,PQ'*',U'2S!-O\W"SDXW/4&DF\RB(B(/#!&@4X\"DC.GUP@X&%TD*
M17@L@$V8-2,8\DE08X+U"Q[]58 =@"2B,EMMM8-U)-(Z\C$!N"U@;352]3E5
M#'RRHB8GROT5'77,H:5>'G68 <#T<0#@!!58_T[)D*2-SP"$"@$(@.$* #@
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MT8<G7.-1 ##!+/(@%!$2P0[6&P!(J, 4!1 @A 7  F)*D@H!6,08*J-)(+!
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M9O1F0BSQ@&2D9T5K6A=63DURA@=WZU4("' :!2C %4(PQOE(8( "D D&)#$
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MU^*!;8HJ;"F# 4@/&**) *B@L@ $7EP# _@*^[L_$< !'E $H? AG"M!B1@
M/P"BBLJA/#R)E3  63! @[",2-!"!FC"7U0AFC <'_J%/S@&+:0HB.*A#2J&
M>F2FCK*>N-/%+6@%'I@G'12'&1B:[G@C86D#G[*#.%B)(C@"N3@"@2@"-KB+
M//&!N]@2!V@(<@2-APJ(;0K'O=F@/.B%87P#!\@*_C@[533&,XBAS[F+=8"J
M;_0"<>@C<LNA4RBB6#B!H4%(LO/'$@J 8:@&$=C^E=&S"9S(15TQG"(XA=P2
MI9\  ."  8L@O6Z(Q7A @GXX@/3@-:BJ";GXBO/QN%FT%223&,T1 $Q,QU2
M!99@!)3Q01. C $P0EU0FB>(HSFJ(RK(HI2"O$-2!'T 2')KB\2#@W"(B.=P
M #]@1W5005R(R!6,!CLA(C]"1UC( RWX"KL,H7MH@#82(GP81DC0!X] B$&:
MC"/(1] I3-9\1@<(@'Z(.V] AYBCJ+=CG:E0/#Y(@C0"@ &0#),P.8H@+:_D
MNM=#ARZ 3490C=/QB'G(H7G:LZVSJ]4DHF)2I8J0#<!L!*(X/DB 36P(!)3+
M-E0B#$4( =.+"#48@ /^L,U^:  ?P@09@*>^L\S.' 4RS FX*P+< ]!&:(2
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M!9UB)R,*"+!ZBB@\)O<#B.54"9VZ7%&Z#S*0"Z8L!S: A*_PDG"X"EJ0 4-
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M_62%XI%H> 8!B&8 $[BL?+Z8"X6^))XO$TA96-%/(W8QDXXS!P+7<Q+7^7J
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M'9J'Z"K5]>\F6NI8F>X1CYNI?(H$D (5AY\<*4YRR"*):+2>2*%=.06=,O"
M%8%51@5&X(&O$ -I8@46=F&3V/"I(@=M=9T"'P 11W$&NN]-F ]2^NS^CO+8
M,3G^_2#LHV\Y;5KUB,M+#:N(F-$E!7,/_0.H(X-(^=B']=8L7Z#Z@A7O.0$0
MB('JP'(Y?YM!?8,A$-;4MNT<@@0L\(UORM[9MM+:/HO:FXQR#(!_,'1K.@7^
M*XT0' B'X4X&)DYTC8HFWS"/..?SMYER31@!8DJ )#CQ4?^8[%:Y1K"#Q!D
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M(#Q=)(  -\SA'$/@-A, @ $IQ"*@Q/5(!0C@'F]L@!SA,( PCG&% # C[>A
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M$ J @ &\ ;Q"B C=A/ &1SH@!P#0[MIR@#P /-4'P<L!/8TK@"$Z)94ARAA
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MR']L2(%O"(?\%X#T%X?G]X;+QX9KZ(9\^'USV(8%:'YF6(=_Z'SP=X9UR("
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0(!F2(CF2)%F2)CD700  .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
